<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006087</article-id><article-id pub-id-type="pmc">PMC11859928</article-id><article-id pub-id-type="doi">10.3390/ph18020275</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00275</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Design, Synthesis, and Antiproliferative Activity of Novel Indole/1,2,4-Triazole Hybrids as Tubulin Polymerization Inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mahmoud</surname><given-names>Esraa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceuticals-18-00275" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7015-7124</contrib-id><name><surname>Abdelhamid</surname><given-names>Dalia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-pharmaceuticals-18-00275" ref-type="aff">2</xref><xref rid="fn1-pharmaceuticals-18-00275" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4005-982X</contrib-id><name><surname>Mohammed</surname><given-names>Anber F.</given-names></name><xref rid="af3-pharmaceuticals-18-00275" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8196-2612</contrib-id><name><surname>Almarhoon</surname><given-names>Zainab M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af4-pharmaceuticals-18-00275" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4845-3191</contrib-id><name><surname>Br&#x000e4;se</surname><given-names>Stefan</given-names></name><xref rid="af5-pharmaceuticals-18-00275" ref-type="aff">5</xref><xref rid="c1-pharmaceuticals-18-00275" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Youssif</surname><given-names>Bahaa G. M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af3-pharmaceuticals-18-00275" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9517-8650</contrib-id><name><surname>Hayallah</surname><given-names>Alaa M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-pharmaceuticals-18-00275" ref-type="aff">3</xref><xref rid="af6-pharmaceuticals-18-00275" ref-type="aff">6</xref><xref rid="c1-pharmaceuticals-18-00275" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Abdel-Aziz</surname><given-names>Mohamad</given-names></name><xref rid="af2-pharmaceuticals-18-00275" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Moreau</surname><given-names>Emmanuel</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00275"><label>1</label>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Deraya University, Minia 2460271, Egypt; <email>esraataha505@yahoo.com</email></aff><aff id="af2-pharmaceuticals-18-00275"><label>2</label>Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia 2431436, Egypt; <email>dalia_abdelhameed@mu.edu.eg</email> (D.A.); <email>abulnil@hotmail.com</email> (M.A.-A.)</aff><aff id="af3-pharmaceuticals-18-00275"><label>3</label>Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt; <email>anber_pharm_2006@yahoo.com</email> (A.F.M.); <email>bgyoussif2@gmail.com</email> (B.G.M.Y.)</aff><aff id="af4-pharmaceuticals-18-00275"><label>4</label>Department of Chemistry, College of Science, King Saud University, Riyadh 11451, Saudi Arabia; <email>zalmarhoon@ksu.edu.sa</email></aff><aff id="af5-pharmaceuticals-18-00275"><label>5</label>Institute of Biological and Chemical Systems, IBCS-FMS, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany</aff><aff id="af6-pharmaceuticals-18-00275"><label>6</label>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sphinx University, New-Assiut 71515, Egypt</aff><author-notes><corresp id="c1-pharmaceuticals-18-00275"><label>*</label>Correspondence: <email>braese@kit.edu</email> (S.B.); <email>alaa_hayalah@yahoo.com</email> (A.M.H.)</corresp><fn id="fn1-pharmaceuticals-18-00275"><label>&#x02020;</label><p>Current address: Raabe College of Pharmacy, Ohio Northern University, Ada, OH 45810, USA.</p></fn></author-notes><pub-date pub-type="epub"><day>19</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>275</elocation-id><history><date date-type="received"><day>25</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>16</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives:</bold> New indole/1,2,4-triazole hybrids were synthesized and tested for antiproliferative activity against the NCI 60 cell line as tubulin polymerization inhibitors. <bold>Methods:</bold> All final compounds, <bold>6a</bold>&#x02013;<bold>j</bold> and <bold>7a</bold>&#x02013;<bold>j</bold> were evaluated at a single concentration of 10 &#x000b5;M against a panel of sixty cancer cell lines. <bold>Results:</bold> Compounds <bold>7a</bold>&#x02013;<bold>j</bold>, featuring the NO-releasing oxime moiety, exhibited superior anticancer activity to their precursor ketones <bold>6a</bold>&#x02013;<bold>j</bold> across all tested cancer cell lines. Compounds <bold>6h</bold>, <bold>7h</bold>, <bold>7i</bold>, and <bold>7j</bold> were chosen for five-dose evaluations against a comprehensive array of 60 human tumor cell lines. The data showed that all tested compounds had significant anticancer activity throughout the nine tumor subpanels studied, with selectivity ratios ranging from 0.52 to 2.29 at the GI<sub>50</sub> level. Compounds <bold>7h</bold> and <bold>7j</bold> showed substantial anticancer effectiveness against most cell lines across nine subpanels, with GI<sub>50</sub> values ranging from 1.85 to 5.76 &#x000b5;M and 2.45 to 5.23 &#x000b5;M. Compounds <bold>6h</bold>, <bold>7h</bold>, <bold>7i</bold>, and <bold>7j</bold> were assessed for their inhibitory effects on tubulin polymerization. <bold>Conclusions:</bold> The results showed that compound <bold>7i</bold>, an oxime-based derivative, was the most effective at blocking tubulin, with an IC<sub>50</sub> value of 3.03 &#x000b1; 0.11 &#x000b5;M. This was compared to the standard drug CA-4, which had an IC<sub>50</sub> value of 8.33 &#x000b1; 0.29 &#x000b5;M. Additionally, cell cycle analysis and apoptosis assays were performed for compound <bold>7i</bold>. Molecular computational investigations have been performed to examine the binding mode of the most effective compounds to the target enzyme.</p></abstract><kwd-group><kwd>NCI</kwd><kwd>cancer</kwd><kwd>CA-4</kwd><kwd>tubulin</kwd><kwd>colchicine</kwd><kwd>anticancer</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00275"><title>1. Introduction</title><p>Cancer is a set of disorders that spread to other regions of the body [<xref rid="B1-pharmaceuticals-18-00275" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-18-00275" ref-type="bibr">2</xref>]. Cancer is the world&#x02019;s second greatest cause of death, after cardiovascular diseases, and hence a significant health burden [<xref rid="B3-pharmaceuticals-18-00275" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-18-00275" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceuticals-18-00275" ref-type="bibr">5</xref>]. There are numerous successful cancer treatment options, but some have adverse effects. For example, certain cancer cells develop resistance to medications, radiotherapy has limitations, and surgery is frequently required. This demonstrates the importance of finding alternative, successful treatments that work in different ways [<xref rid="B6-pharmaceuticals-18-00275" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceuticals-18-00275" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-18-00275" ref-type="bibr">8</xref>].</p><p>Tubulin has been identified as an important therapeutic target for cancer treatment due to its role in cell division, signaling, protein transport, and cellular structure maintenance [<xref rid="B9-pharmaceuticals-18-00275" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-18-00275" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceuticals-18-00275" ref-type="bibr">11</xref>]. Researchers have investigated numerous tubulin inhibitors with various scaffolds, most notably combretastatin A-4 [CA-4 (<bold>I</bold>), <xref rid="pharmaceuticals-18-00275-f001" ref-type="fig">Figure 1</xref>], a prominent tubulin polymerization inhibitor that binds to the colchicine site in tubulin and effectively suppresses cancer cell proliferation at low nanomolar concentrations [<xref rid="B12-pharmaceuticals-18-00275" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceuticals-18-00275" ref-type="bibr">13</xref>]. However, the isomerization of the cis-double bond to a more stable and inactive trans-form hindered its potential therapeutic application [<xref rid="B14-pharmaceuticals-18-00275" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceuticals-18-00275" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceuticals-18-00275" ref-type="bibr">16</xref>]. Consequently, there is growing interest in developing innovative tubulin inhibitors for cancer treatment.</p><p>Many indole-based compounds are known to be potent bioactive molecules, particularly as antitumor agents with strong tubulin polymerization inhibition [<xref rid="B17-pharmaceuticals-18-00275" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-18-00275" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceuticals-18-00275" ref-type="bibr">19</xref>]. Pecnard et al. [<xref rid="B20-pharmaceuticals-18-00275" ref-type="bibr">20</xref>] developed a series of cyclic bridging analogs of isocombretastatin A-4 (isoCA-4, compound <bold>II</bold>, <xref rid="pharmaceuticals-18-00275-f001" ref-type="fig">Figure 1</xref>) with phenyl or pyridine linkers. A study of the structure-activity relationship (SAR) reveals that the presence of quinaldine (ring A), pyridine (linker), and indole (ring B) in the same molecule is required for its cytotoxic activity. Compound <bold>III</bold> (<xref rid="pharmaceuticals-18-00275-f001" ref-type="fig">Figure 1</xref>) had the most significant antiproliferative effect against various cancer cell lines among all evaluated compounds. Compound <bold>III</bold> showed strong antiproliferative activity against the multi-drug resistant K562R cell line; it was 1.5 times and 12 times more effective than the reference compounds, isoCA-4 and CA-4. Compound <bold>III</bold> efficiently reduced tubulin polymerization in both in vitro and cellular contexts, producing cell cycle arrest in the G2/M phase. A molecular docking study of <bold>III</bold> in the colchicine binding site of the tubulin &#x003b2; subunit showed that the overall binding mode was the same as that found for isoCA-4. The quinaldine ring system fit into the lipophilic pocket normally occupied by the trimethoxyphenyl nucleus of isoCA-4, and the indole ring was placed similarly to isoCA-4&#x02032;s B ring [<xref rid="B20-pharmaceuticals-18-00275" ref-type="bibr">20</xref>].</p><p>Researchers conducted numerous studies to constrain the cis-orientation of the ethylene bond in CA-4 by substituting it with rigid heterocyclic rings, particularly triazoles [<xref rid="B12-pharmaceuticals-18-00275" ref-type="bibr">12</xref>,<xref rid="B21-pharmaceuticals-18-00275" ref-type="bibr">21</xref>]. Additionally, many studies have documented significant antiproliferative activity of numerous 1,2,4-triazole derivatives as tubulin inhibitors [<xref rid="B22-pharmaceuticals-18-00275" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceuticals-18-00275" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceuticals-18-00275" ref-type="bibr">24</xref>]. Moreover, derivatives of 1,2,4-triazole have been thoroughly investigated for their antibacterial, antifungal, and antiviral activities, especially as inhibitors of metallo-&#x003b2;-lactamases [<xref rid="B25-pharmaceuticals-18-00275" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceuticals-18-00275" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceuticals-18-00275" ref-type="bibr">27</xref>].</p><p>In a recent study [<xref rid="B28-pharmaceuticals-18-00275" ref-type="bibr">28</xref>], the authors reported a group of 6-aryl-2-(3,4,5-trimethoxyphenyl)thiazolo [3,2-b][1,2,4]triazoles that might be able to reduce tubulin polymerization by attaching to the colchicine domain on tubulin. Among the compounds produced, <bold>IV</bold> (<xref rid="pharmaceuticals-18-00275-f001" ref-type="fig">Figure 1</xref>) demonstrated significant efficacy against the SGC-7901 cancer cell line, with an IC<sub>50</sub> value of 0.21 &#x000b5;M. The data indicated that compound <bold>IV</bold> may function as an antitubulin, inducing cell cycle arrest in the G2/M phase.</p><p>Oximes are hydroxy-imine derivatives popular in medicinal chemistry because they are simple to synthesize from carbonyl compounds and have diverse biological effects [<xref rid="B29-pharmaceuticals-18-00275" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceuticals-18-00275" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-18-00275" ref-type="bibr">31</xref>]. Concerning tubulin-binding oximes, the curacin A oxime analog <bold>V</bold> (<xref rid="pharmaceuticals-18-00275-f002" ref-type="fig">Figure 2</xref>) blocks tubulin polymerization like CA-4, with the oxime group acting as a bioisosteric substitute for a (Z)-alkene group [<xref rid="B32-pharmaceuticals-18-00275" ref-type="bibr">32</xref>]. Moreover, diaryl methyl oxime <bold>VI</bold> (<xref rid="pharmaceuticals-18-00275-f002" ref-type="fig">Figure 2</xref>), which has an indole ring, has demonstrated significant inhibitory effects on tubulin polymerization [<xref rid="B33-pharmaceuticals-18-00275" ref-type="bibr">33</xref>].</p><p>Inspired by previous findings of indole and/or 1,2,4-triazole derivatives as tubulin polymerization inhibitors and in continuation of our efforts to develop novel antitumor agents [<xref rid="B34-pharmaceuticals-18-00275" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-18-00275" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceuticals-18-00275" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceuticals-18-00275" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceuticals-18-00275" ref-type="bibr">38</xref>], we aim to combine these two moieties into a unique molecular framework to develop a novel series of indole-triazole hybrids <bold>6a</bold>&#x02013;<bold>j</bold> and <bold>7a</bold>&#x02013;<bold>j</bold> (<xref rid="pharmaceuticals-18-00275-f003" ref-type="fig">Figure 3</xref>). The new compounds comprise the three main parts of CA-4: ring A, which is an indole ring; ring B, which is a substituted phenyl group; and the linker, which is the 1,2,4-triazole moiety. We employed oxime formation (<bold>7a</bold>&#x02013;<bold>j</bold>) to enhance the efficacy of <bold>6a</bold>&#x02013;<bold>j</bold> analogs. This mechanism could either augment chemotherapeutic activity through nitric oxide release or enhance binding to the colchicine binding site via hydrogen bond formation. This study presents comprehensive synthesis pathways, antiproliferative properties, and tubulin polymerization inhibitory effects.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-18-00275"><title>2. Results and Discussion</title><sec id="sec2dot1-pharmaceuticals-18-00275"><title>2.1. Chemistry</title><p><xref rid="pharmaceuticals-18-00275-sch001" ref-type="fig">Scheme 1</xref> outlines the synthetic pathway for synthesizing new compounds <bold>6a</bold>&#x02013;<bold>j</bold> and <bold>7a</bold>&#x02013;<bold>j</bold>. Using POCl<sub>3</sub> and DMF in the Vielsmeier-Haack reaction on indole produced a high yield of 1<italic toggle="yes">H</italic>-indole-3-carbaldehyde (<bold>1</bold>) [<xref rid="B39-pharmaceuticals-18-00275" ref-type="bibr">39</xref>]. KMnO<sub>4</sub> in acetone oxidized 1<italic toggle="yes">H</italic>-indole-3-carbaldehyde (<bold>1</bold>), forming its acid counterpart (<bold>2</bold>) [<xref rid="B40-pharmaceuticals-18-00275" ref-type="bibr">40</xref>]. The oxidation product <bold>2</bold> was mixed with an excess of ethanol and a catalytic amount of concentrated H<sub>2</sub>SO<sub>4</sub> to synthesize the ethyl ester derivative (<bold>3</bold>) [<xref rid="B41-pharmaceuticals-18-00275" ref-type="bibr">41</xref>]. 1<italic toggle="yes">H</italic>-indole-3-carbohydrazide (<bold>4</bold>) was synthesized by stirring the ethyl ester (<bold>3</bold>) with hydrazine monohydrate (95%) [<xref rid="B42-pharmaceuticals-18-00275" ref-type="bibr">42</xref>]. After refluxing product <bold>4</bold> with allyl/phenyl isothiocyanate and adding 2 N KOH solution, the thiol derivatives <bold>5a</bold>&#x02013;<bold>b</bold> were formed in good yields [<xref rid="B42-pharmaceuticals-18-00275" ref-type="bibr">42</xref>]. The target ketone compounds <bold>6a</bold>&#x02013;<bold>j</bold> were synthesized by combining compounds <bold>5a</bold>&#x02013;<bold>b</bold>, phenacyl bromide derivatives, and TEA in acetonitrile.</p><p>Compounds <bold>6a</bold>&#x02013;<bold>j</bold> were validated by <sup>1</sup>H NMR, <sup>13</sup>C NMR spectroscopy, and elemental microanalysis. As an example, the <sup>1</sup>H NMR spectrum of <bold>6b</bold> exhibited a typical pattern of the indole scaffold at their anticipated chemical shifts. Also, the spectrum displayed a distinctive singlet signal at &#x003b4; = 3.85 ppm for O-CH<sub>3</sub> and &#x003b4; = 4.94 ppm for the methylene S-CH<sub>2</sub> linker, confirming the alkylation process. The signals characteristic of the allyl moiety in 6b manifest as a doublet at &#x003b4;: 4.82 ppm corresponding to (N-CH<sub>2</sub>-CH=CH<sub>2</sub>), a doublet of doublets in the range of &#x003b4;: 4.90&#x02013;4.74 ppm and &#x003b4;: 5.23&#x02013;4.26 ppm for (N-CH<sub>2</sub>-CH=CH<sub>2</sub>), and a multiplet signal at &#x003b4;: 6.10&#x02013;6.01 ppm associated with (N-CH<sub>2</sub>-CH=CH<sub>2</sub>). The <sup>13</sup>C NMR spectrum of compound <bold>6b</bold> exhibited a signal of C=O in the range of &#x003b4;: 194.48&#x02013;193.00 ppm; furthermore, all other carbon signals appeared at their anticipated chemical shifts.</p><fig position="anchor" id="pharmaceuticals-18-00275-sch001"><object-id pub-id-type="pii">pharmaceuticals-18-00275-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Synthesis of target compounds <bold>6a</bold>&#x02013;<bold>j</bold> and <bold>7a</bold>&#x02013;<bold>j</bold>.</p></caption><graphic xlink:href="pharmaceuticals-18-00275-sch001" position="float"/></fig><list list-type="simple"><list-item><p><bold>Reagent and reaction conditions:</bold> (a) DMF, POCl<sub>3</sub>, ice, 8 h, 84% yield; (b) KMnO<sub>4</sub>, acetone, rt, 12&#x02013;24 h, 70% yield; (c) absolute ethanol, H<sub>2</sub>SO<sub>4</sub>, 70 &#x000b0;C, 20 h; (d) ethanol, NH<sub>2</sub>-NH<sub>2</sub>&#x000b7;H<sub>2</sub>O, 150 &#x000b0;C, 8 h; (e) allyl/phenyl isothiocyanate, 150 &#x000b0;C, 3 h; (f) KOH, 150 &#x000b0;C, overnight; (g) TEA, acetonitrile, 100 &#x000b0;C, 4 h; and (h) NH<sub>2</sub>OH.HCl, CH<sub>3</sub>COONa, 50&#x02013;70 &#x000b0;C, 2&#x02013;8 h.</p></list-item></list><p>Oximes <bold>7a</bold>&#x02013;<bold>j</bold> were synthesized by refluxing the corresponding ketones <bold>6a</bold>&#x02013;<bold>j</bold> with hydroxylamine hydrochloride and anhydrous sodium acetate in absolute ethanol, resulting in acceptable yields of the target compounds <bold>7a</bold>&#x02013;<bold>j</bold>. The chemical structure of oximes <bold>7a</bold>&#x02013;<bold>j</bold> was confirmed by <sup>1</sup>H NMR, <sup>13</sup>C NMR spectroscopy, and elemental analysis. The <sup>1</sup>H NMR spectrum of compound <bold>7c</bold> showed a singlet signal for methyl protons at &#x003b4;: 2.24 ppm and a significant singlet signal at &#x003b4;: 11.88 ppm, which corresponded to the OH group of the oxime moiety. The upfield shift of the S-CH<sub>2</sub> linker adjacent to C=N from &#x003b4;: 4.94 ppm to &#x003b4;: 4.43 ppm is another distinguishing feature of the oxime spectrum. This occurs because the N atom in oximes is less electronegative than the O atom in ketones. All other protons manifest at their anticipated chemical changes. The <sup>13</sup>C NMR of compound <bold>7c</bold> displayed a shift of C=O signals from &#x003b4;: 194.48&#x02013;193.00 ppm to &#x003b4;: 152.18&#x02013;152.63 ppm for the C=N group. All remaining carbons exhibit their anticipated chemical shifts. There is only one diastereomer detected.</p></sec><sec id="sec2dot2-pharmaceuticals-18-00275"><title>2.2. Biology</title><sec id="sec2dot2dot1-pharmaceuticals-18-00275"><title>2.2.1. Evaluation of Anticancer Efficacy</title><sec><title>In Vitro One Dose NCI Assay</title><p>The National Cancer Institute (NCI), Bethesda, USA, selected the final compounds <bold>6a</bold>&#x02013;<bold>j</bold> and <bold>7a</bold>&#x02013;<bold>j</bold> for in vitro anticancer screening [<xref rid="B43-pharmaceuticals-18-00275" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceuticals-18-00275" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceuticals-18-00275" ref-type="bibr">45</xref>]. An initial in vitro single-dose anticancer experiment was performed with the entire NCI 60 cell lines derived from nine tumor subpanel cancer cell lines. The results for each compound were illustrated as a mean graph showing the percentage growth of treated cells compared to untreated control cells (see <xref rid="app1-pharmaceuticals-18-00275" ref-type="app">Supplementary Materials</xref>). <xref rid="pharmaceuticals-18-00275-t001" ref-type="table">Table 1</xref> displays the percentage of growth inhibition for the most active derivatives <bold>6h</bold>, <bold>7h</bold>, <bold>7i</bold>, and <bold>7j</bold>.</p><p>The NCI findings indicated weak to moderate anticancer efficacy for indole-N-allyl-triazole-phenyl ethanone derivatives (<bold>6a</bold>&#x02013;<bold>e</bold>) and their corresponding oxime derivatives (<bold>7a</bold>&#x02013;<bold>e</bold>). Compound <bold>7d</bold> exhibited modest anticancer efficacy against eleven cell lines, with growth inhibition percentage ranging from 34% to 47%. Compound <bold>7e</bold> exhibited moderate anticancer efficacy against HL-60(TB), K-562, MOLT-4, HCT-116, UACC-62, UO-31, T-47D, and MDA-MB-468 cell lines, with growth inhibition percentages ranging from 35% to 46.5%. Compounds <bold>6a</bold>, <bold>6c</bold>, and <bold>7c</bold> demonstrated moderate anticancer activity against a single cell line each: <bold>6a</bold> against UO-31 with a growth inhibition of 35%, <bold>6c</bold> against HOP-92 with a growth inhibition of 50%, and <bold>7c</bold> against UO-31 with a growth inhibition of 35%. Conversely, compounds <bold>6b</bold>, <bold>6d</bold>, <bold>6e</bold>, <bold>7a</bold>, and <bold>7b</bold> exhibited minimal anticancer activity across all cell lines.</p><p>Conversely, the NCI results showed that the anticancer effects of indole-N-phenyl-triazole-phenyl ethanone derivatives (<bold>6f</bold>&#x02013;<bold>j</bold>) and their oxime derivatives (<bold>7f</bold>&#x02013;<bold>j</bold>) were greater than those seen with similar ketones and oximes that contained the N-allyl triazole moiety. Among all evaluated compounds, <bold>6h</bold>, <bold>7h</bold>, <bold>7i</bold>, and <bold>7j</bold> exhibited the most effective anticancer activity against all tested cancer cell lines.</p><p>Compound <bold>6h</bold> exhibited complete cell death across ten cancer cell lines, with cell growth inhibition percentages varying from 101 to 141. It also exhibited significant anticancer efficacy, with cell growth inhibition percentages ranging from 67% to 99% across twenty-five cell lines, as demonstrated in <xref rid="pharmaceuticals-18-00275-t001" ref-type="table">Table 1</xref>. Compound <bold>7h</bold> resulted in complete cell death in thirty-six cell lines, exhibiting a cell growth inhibition percentage ranging from 105.5 to 200. Compound <bold>7h</bold> demonstrated significant anticancer efficacy against sixteen cell lines, with cell growth inhibition percentages ranging from 72% to 98%, while it showed modest activity against the other evaluated cancer cell lines.</p><p>Compound <bold>7i</bold> induced complete cell death in forty-nine cell lines, exhibiting cell growth inhibition percentages from 106.14 to 200. It demonstrated significant anticancer efficacy against eight cell lines, with inhibition percentages ranging from 86 to 99. It also demonstrated moderate activity against the 786-0 and A498 cell lines, with inhibition percentages of 65 and 38, respectively, as detailed in <xref rid="pharmaceuticals-18-00275-t001" ref-type="table">Table 1</xref>. Compound <bold>7j</bold> exhibited total cell death across twenty-eight cell lines, with cell growth inhibition percentages ranging from 102 to 200. It demonstrated significant anticancer activity against twenty-four cell lines, with cell growth inhibition percentages between 69.48 and 99.26. It also demonstrated moderate anticancer activity against six cell lines, with cell growth inhibition percentages ranging from 52 to 66.</p><p>The data indicated that indole derivatives containing an oxime moiety and their corresponding ketones with an N-phenyl triazole backbone exhibited superior anticancer activity compared to those with an N-allyl triazole backbone, suggesting the N-phenyl moiety&#x02019;s significant role in enhancing anticancer efficacy. Additionally, compounds <bold>7a</bold>&#x02013;<bold>j</bold> with the NO-releasing oxime moiety showed more anticancer activity than their precursor ketones <bold>6a</bold>&#x02013;<bold>j</bold> across all examined cancer cell lines. The increased activity may be attributed to these compounds&#x02019; ability to produce NO, which is cytotoxic, in contrast to their precursor ketones. This demonstrates the significance of the oxime moiety in the anticancer efficacy of the target drugs.</p></sec><sec><title>In Vitro Five-Dose Full NCI 60 Cell Panel Assay</title><p>Compounds <bold>6h</bold>, <bold>7h</bold>, <bold>7i</bold>, and <bold>7j</bold>, the most efficacious derivatives, were chosen for a five-dose experiment against a panel of 60 human tumor cell lines across nine tumor subpanels. The evaluated derivatives were incubated with five different dosages (<xref rid="app1-pharmaceuticals-18-00275" ref-type="app">Supplementary Materials</xref>). The data was used to develop log concentration versus percentage growth inhibition curves, and three parameters (GI<sub>50</sub>, TGI, and LC<sub>50</sub>) were calculated for each cell line. The growth inhibitory activity (GI<sub>50</sub>) value signifies the concentration of a compound that causes a 50% decrease in net cell growth; the total growth inhibition (TGI) value indicates the concentration that results in complete growth inhibition, whereas the LC<sub>50</sub> value reflects the concentration that leads to a 50% reduction of initial cells following a 48 h incubation period. The selectivity of a compound is quantified by the extent to which the whole panel MID (the mean sensitivity of all cell lines to the test agent) is less than or equal to the subpanel MID for each individual cell line. Ratios ranging from three to six indicate moderate selectivity; ratios exceeding six indicate high selectivity for the specific cell line, but chemicals that do not meet either requirement are categorized as nonselective [<xref rid="B46-pharmaceuticals-18-00275" ref-type="bibr">46</xref>]. The outcomes are presented in <xref rid="pharmaceuticals-18-00275-t002" ref-type="table">Table 2</xref>, <xref rid="pharmaceuticals-18-00275-t003" ref-type="table">Table 3</xref>, <xref rid="pharmaceuticals-18-00275-t004" ref-type="table">Table 4</xref> and <xref rid="pharmaceuticals-18-00275-t005" ref-type="table">Table 5</xref>.</p><p>The data revealed that all tested compounds demonstrated broad anticancer efficacy across all nine tumor subpanels examined, with selectivity ratios ranging from 0.52 to 2.29 at the GI<sub>50</sub> level. Compounds <bold>7h</bold> and <bold>7j</bold> (<xref rid="pharmaceuticals-18-00275-t003" ref-type="table">Table 3</xref> and <xref rid="pharmaceuticals-18-00275-t005" ref-type="table">Table 5</xref>) showed remarkable anticancer activity against most of the tested cell lines across nine different subpanels, with GI<sub>50</sub> values for most of the cells ranging from 1.85 to 5.76 &#x000b5;M and 2.45 to 5.23 &#x000b5;M, respectively. When tested against nine different types of cancer cells, compound <bold>7i</bold> (<xref rid="pharmaceuticals-18-00275-t004" ref-type="table">Table 4</xref>) showed strong anticancer activity, with GI<sub>50</sub> values ranging from 2.10 to 3.23 &#x000b5;M. Also, Compound <bold>6h</bold> (<xref rid="pharmaceuticals-18-00275-t002" ref-type="table">Table 2</xref>) showed enhanced anticancer activity against most of the tested cell lines across nine separate subpanels, with GI<sub>50</sub> values for most of the cells ranging from 8.42 to 33.48 &#x000b5;M.</p></sec><sec><title>Tubulin Polymerization Inhibitory Assay</title><p>The impact of new synthetic compounds <bold>6h</bold>, <bold>7h</bold>, <bold>7i</bold>, and <bold>7j</bold> on tubulin polymerization, with CA-4 as a reference compound [<xref rid="B34-pharmaceuticals-18-00275" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-18-00275" ref-type="bibr">35</xref>], is presented in <xref rid="pharmaceuticals-18-00275-t006" ref-type="table">Table 6</xref>. The results of this in vitro experiment are consistent with the one-dose and five-dose NCI assays.</p><p>Compound <bold>7i</bold> (R = Ph, R<sub>1</sub> = Br; oxime-based derivative) was the most potent tubulin inhibitor, with an IC<sub>50</sub> value of 3.03 &#x000b1; 0.11&#x000b5;M, compared to the reference CA-4 (IC<sub>50</sub> value of 8.33 &#x000b1; 0.29 &#x000b5;M). Compound <bold>7i</bold> was found to be approximately three times as effective as CA-4 as a tubulin inhibitor. With an IC<sub>50</sub> value of 6.26 &#x000b1; 0.15 &#x000b5;M, compound <bold>7j</bold> (R = Ph, R<sub>1</sub> = Cl; oxime-based derivative) was the second most effective tubulin inhibitor. It was half as potent as compound <bold>7i</bold> but still better than the standard compound CA-4. The data suggest that the bromine atom at the <italic toggle="yes">para</italic>-position of ring B is more favorable to activity than the chlorine atom.</p><p>Compounds <bold>6h</bold> (R = Ph, R<sub>1</sub> = CH<sub>3</sub>; ketone-based derivative) and <bold>7h</bold> (R = Ph, R<sub>1</sub> = CH<sub>3</sub>; oxime-based derivative) had the lowest potency as tubulin inhibitors, at IC<sub>50</sub> values of 9.50 &#x000b1; 0.30 &#x000b5;M and 18.37 &#x000b1; 0.70 &#x000b5;M, respectively. In comparison, CA-4 had an IC<sub>50</sub> of 8.33 &#x000b1; 0.29 &#x000b5;M, demonstrating that compounds <bold>6h</bold> and <bold>7h</bold> are less potent tubulin inhibitors than the reference drug CA-4.</p><p>The activity of compound <bold>6h</bold> was three times lower than compound <bold>7i</bold> and 1.5 times lower than compound <bold>7j</bold>. This shows how important the type of substitution at the <italic toggle="yes">para</italic>-position of the phenyl ring B is, with activity going up in the order of Br &#x0003e; Cl &#x0003e; CH<sub>3</sub>.</p><p>Finally, these results support the in vitro NCI results, showing that the oxime-based derivatives with a phenyl group at the 1,2,4-triazole ring are much more effective than other derivatives. This underscores the significance of the oxime group in the efficacy of these compounds.</p></sec></sec><sec id="sec2dot2dot2-pharmaceuticals-18-00275"><title>2.2.2. Cell Cycle Analysis and Detection of Apoptosis</title><sec><title>Cell Cycle Analysis</title><p>The impact of compound <bold>7i</bold> on cell cycle progression was investigated in MDA-MB 231 breast cancer cells. The breast cancer (MDA-MB 231) cell line was treated for 24 h with an IC<sub>50</sub> concentration of <bold>7i</bold>. The cell line was handled with PI/Annexin V, and flow cytometry was utilizing a BD FACS Caliber [<xref rid="B47-pharmaceuticals-18-00275" ref-type="bibr">47</xref>]. The results (<xref rid="pharmaceuticals-18-00275-f004" ref-type="fig">Figure 4</xref>) indicated that MDA-MB 231 cells subjected to compound <bold>7i</bold> exhibited a substantial accumulation of 83% in the G0/G1 phase following 24 h of incubation. This indicates a cell cycle arrest at the G1 phase transition.</p></sec><sec><title>Assay for Induction of Apoptosis</title><p>The MDA-MB 231 cell was labeled with Annexin V/PI, cultured for 24 h, and examined to assess the capacity of <bold>7i</bold> to induce apoptosis. Examining early and late apoptosis demonstrated that compound <bold>7i</bold> elicited substantial apoptosis, accompanied by a necrosis rate 3.88 (<xref rid="pharmaceuticals-18-00275-f005" ref-type="fig">Figure 5</xref> and <xref rid="pharmaceuticals-18-00275-f006" ref-type="fig">Figure 6</xref>).</p></sec></sec></sec><sec id="sec2dot3-pharmaceuticals-18-00275"><title>2.3. Molecular Modelling</title><p>Docking simulations of the most potent compounds, <bold>6h</bold>, <bold>7h</bold>, <bold>7i</bold>, and <bold>7j</bold>, were performed at the &#x003b1;/&#x003b2;-tubulin to explore their potential binding modes and rationalize the biological results. The X-ray crystal structure of Combretastatin A4 (cis-CA-4) bound to its tubulin complex was used in this investigation [PBD: 5LYJ] [<xref rid="B48-pharmaceuticals-18-00275" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceuticals-18-00275" ref-type="bibr">49</xref>]. For ligand, protein, and docking simulations utilizing MOE software 2019, the Amber10:EHT forcefield and reaction field solvation model were applied [<xref rid="B50-pharmaceuticals-18-00275" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceuticals-18-00275" ref-type="bibr">51</xref>].</p><p>CA-4 occupies the same space as the microtubule-destabilizing agent, colchicine, and binds to the colchicine binding site (<xref rid="pharmaceuticals-18-00275-f007" ref-type="fig">Figure 7</xref>). The protocol was initially validated by redocking the co-crystallized ligand, where the <italic toggle="yes">RMSD</italic> value obtained for the docked ligand was 0.77 &#x000c5; (<italic toggle="yes">S1</italic>). Docked compounds displayed docking scores ranging from &#x02212;7.39 to &#x02212;8.31 kcal/mol compared with CA-4 (&#x02212;8.68 kcal/mol). The simulation results of the compounds were compared with CA-4, and the data are shown in (<xref rid="pharmaceuticals-18-00275-t007" ref-type="table">Table 7</xref>). The visualization of the ligand complexes revealed that the oxime-based derivatives <bold>7h</bold>, <bold>7i</bold>, and <bold>7j</bold> exhibit better binding affinity than the ketone-based derivative <bold>6h</bold>. The indole ring (ring A) of the oxime-based derivatives <bold>7h</bold>, <bold>7i</bold>, and <bold>7j</bold> is lying in the pocket that allows a stacking interaction between &#x003b2;Asn258 and &#x003b2;Lys352 along with forming pi-H contacts with &#x003b2;Asn258 or &#x003b2;Lys352 residues, (<xref rid="pharmaceuticals-18-00275-f008" ref-type="fig">Figure 8</xref>). The ligand indole NH or H-2 additionally forms an H-bond interaction with &#x003b2;Met259. Furthermore, the indole scaffold is stabilized by forming hydrophobic interactions with residues &#x003b1;Thr179, &#x003b1;Ala180, &#x003b1;Val181, &#x003b2;Asn350, and &#x003b2;Asn349. In addition, the ligand triazole linker donates an H-bond to &#x003b2;Met259 in the <bold>7i</bold> and <bold>7j</bold> complexes and establishes a pi-H contact with &#x003b2;Lys352 in the <bold>7j</bold> complex. Moreover, in the <bold>7h</bold> complex, the N-substituted phenyl moiety establishes pi-H interactions with &#x003b2;Leu248 and &#x003b1;Asn101, and in the <bold>7i</bold> complex, with &#x003b2;Leu248.</p><p>Interestingly, the bulky bromine group in the <bold>7i</bold> complex enables the oxime group to touch the protein interaction surface and donate an H-bond to &#x003b2;Ala317 with 2.05 &#x000c5;. The complexes of the methyl-substituted derivative, <bold>7h</bold>, or the chlorine-substituted one, <bold>7j</bold>, lack H-bond interaction. In addition, the phenyl (ring B) is stacked between &#x003b2;Cys241 and &#x003b2;Leu255 residues within the hydrophobic pocket (<xref rid="pharmaceuticals-18-00275-f009" ref-type="fig">Figure 9</xref>), as well as forming pi-H contact with &#x003b2;Leu255 in the <bold>7h</bold> and <bold>7j</bold> complexes. The presence of a highly lipophilic and hydrophobic bromophenyl group in <bold>7i</bold> may also account for its increased activity when compared to tolyl and chlorophenyl moieties in <bold>7h</bold> and <bold>7j</bold>, respectively.</p><p>On the other hand, in the case of the ketone-based derivative, <bold>6h</bold> (<xref rid="pharmaceuticals-18-00275-f003" ref-type="fig">Figure 3</xref>), the ligand is being upturned so the indole (ring A) is buried in the hydrophobic pocket and stacked between &#x003b2;Cys241 and &#x003b2;Leu255. Also, the ligand N-phenyl triazole loses interactions with &#x003b2;Met259, &#x003b2;Lys352, or &#x003b2;Leu248 at the junction of the binding site compared to the oxime-based derivatives. However, the ligand 4-methylphenyl moiety (ring B) forms pi-H contact with &#x003b1;Val181 and hydrophobic interactions with residues &#x003b1;Thr179, &#x003b2;Asn350, and &#x003b2;Asn349, &#x003b1;Ala180, and &#x003b1;Val181. Furthermore, the alignment of the <bold>7i</bold> complex onto the <italic toggle="yes">cis</italic>-CA-4 one revealed that the 3-HO-4-MeO-substituted ring of <italic toggle="yes">cis</italic>-CA-4 (ring B) superimposes on the indole moiety (ring A) of <bold>7i</bold>. Also, the 4-bromo-phenyl moiety of <bold>7i</bold> is buried deeper inside the pocket than is the 3,4,5-MeO-substituted ring of <italic toggle="yes">cis</italic>-CA-4 (ring B).</p></sec></sec><sec id="sec3-pharmaceuticals-18-00275"><title>3. Materials and Methods</title><sec id="sec3dot1-pharmaceuticals-18-00275"><title>3.1. Chemistry</title><p><bold>General details:</bold> See <xref rid="app2-pharmaceuticals-18-00275" ref-type="app">Appendix A</xref>.</p><p>Compounds <bold>1</bold> [<xref rid="B39-pharmaceuticals-18-00275" ref-type="bibr">39</xref>], <bold>2</bold> [<xref rid="B40-pharmaceuticals-18-00275" ref-type="bibr">40</xref>], <bold>3</bold> [<xref rid="B41-pharmaceuticals-18-00275" ref-type="bibr">41</xref>], <bold>4</bold> [<xref rid="B42-pharmaceuticals-18-00275" ref-type="bibr">42</xref>], and <bold>5a</bold>&#x02013;<bold>b</bold> [<xref rid="B42-pharmaceuticals-18-00275" ref-type="bibr">42</xref>] were synthesized according to previously reported procedures.</p><sec id="sec3dot1dot1-pharmaceuticals-18-00275"><title>3.1.1. Synthesis of 2-((5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4-allyl/phenyl-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-phenylethanone Derivatives (<bold>6a</bold>&#x02013;<bold>j</bold>)</title><p>Compound <bold>5</bold> in an equimolar ratio with phenacyl bromide derivatives (1.00 mol), and TEA (1.00 mol) in 25 mL of acetonitrile were stirred at room temperature for 2 to 4 h. The reaction mixture evaporated to dryness. The residue was crystallized from aqueous ethanol, yielding compounds <bold>6a</bold>&#x02013;<bold>j</bold> in good yields.</p><sec><title>2-((4-Allyl-5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-phenylethanone (<bold>6a</bold>)</title><p>White crystals in (0.109 g, 62% yield); m.p 189&#x02013;193 &#x000b0;C <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.71 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.09&#x02013;8.02 (m, 3H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.75 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.73&#x02013;7.67 (m, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.58 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.50 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.22 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.14 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.10&#x02013;6.01 (m, 1H, N-CH<sub>2</sub>-C<italic toggle="yes"><underline>H</underline></italic>=CH<sub>2</sub>), 5.24 (d, <italic toggle="yes">J</italic><sub>cis</sub> = 12.00 Hz, 1H, N-CH<sub>2</sub>-CH=C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>), 4.95 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 4.88 (d, <italic toggle="yes">J<sub>trans</sub></italic> = 16.00 Hz,1H, N-CH<sub>2</sub>CH=C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 4.82 (d, <italic toggle="yes">J</italic> = 4.6 Hz, 2H, N-C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>-CH=CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 194.48, 151.66, 148.38, 136.39, 135.76, 134.23, 133.01, 129.32, 128.92, 126.09, 125.58, 122.89, 121.23, 120.76, 117.21, 112.32, 99.90, 47.27, 42.3; anal. calcd. for C<sub>21</sub>H<sub>18</sub>ClN<sub>5</sub>OS (374.46): C, 59.50; H, 4.28; N, 16.52; S, 7.56, found: C, 59.31; H, 4.39; N, 16.80; S, 7.64.</p></sec><sec><title>2-((4-Allyl-5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(4-methoxyphenyl) Ethenone (<bold>6b</bold>)</title><p>Yellow crystals in (0.115 g, 49% yield); m.p 191&#x02013;194 &#x000b0;C <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.74 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.09 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 8.03 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.76 (d, <italic toggle="yes">J</italic> = 2.8 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.52 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>,), 7.22 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.14 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.07 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.10&#x02013;6.01 (m, 1H, N-CH<sub>2</sub>-C<italic toggle="yes"><underline>H</underline></italic>=CH<sub>2</sub>), 5.24 (d, <italic toggle="yes">J</italic><sub>cis</sub> = 12.00 Hz, 1H, N-CH<sub>2</sub>-CH=C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>), 4.92&#x02013;4.85 (m, 3H, N-CH<sub>2</sub>CH=C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>+2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 4.82 (d, <italic toggle="yes">J</italic> = 4.60 Hz, 2H, N-C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>-CH=CH<sub>2</sub>), 3.85 (s, 3H, O-CH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 192.30, 164.05, 151.98, 149.20, 136.42, 133.04, 131.32, 128.58, 126.13, 125.52, 122.90, 121.26, 120.77, 117.17, 114.51, 112.34, 101.98, 56.05, 46.72, 41.3; anal. calcd. for C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>S (404.48): C, 65.33; H, 4.98; N, 13.85; S, 7.93, found: C, 65.49; H, 5.12; N, 14.09; S, 8.01.</p></sec><sec><title>2-((4-allyl-5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(<italic toggle="yes">p</italic>-tolyl)ethanone (<bold>6c</bold>)</title><p>Yellow crystals in (0.200 g, 60% yield); m.p 219&#x02013;224 &#x000b0;C <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.72 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.06 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.95 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.74 (d, <italic toggle="yes">J</italic> = 2.8 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.48 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.38 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>) 7.21 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.14 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.09&#x02013;6.01 (m, 1H, N-CH<sub>2</sub>-C<italic toggle="yes"><underline>H</underline></italic>=CH<sub>2</sub>), 5.24 (d, <italic toggle="yes">J</italic><sub>cis</sub> = 12.00 Hz, 1H, N-CH<sub>2</sub>-CH=C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>), 4.90 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 3.83 (d, <italic toggle="yes">J<sub>trans</sub></italic> = 16.00 Hz,1H, N-CH<sub>2</sub>CH=C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 4.82 (d, <italic toggle="yes">J</italic> = 4.60 Hz, 2H, N-C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>-CH=CH<sub>2</sub>), 2.39 (s, 3H, -C<italic toggle="yes"><underline>H</underline></italic><underline><sub>3</sub></underline>); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 193.48, 151.95, 149.05, 144.75, 136.40, 133.27, 133.09, 129.84, 129.05, 126.12, 125.51, 122.86, 121.28, 120.73, 117.16, 112.31, 101.97, 46.72, 41.83, 20.57.; anal. calcd. for C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>OS (388.49): C, 68.02; H, 5.19; N, 14.42; S, 8.25, found: C, 68.31; H, 5.42; N, 14.67; S, 8.34.</p></sec><sec><title>2-((4-Allyl-5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(4-bromophenyl)ethenone (<bold>6d</bold>)</title><p>Yellowish white crystals in (0.144 g, 41% yield); m.p 227&#x02013;231 &#x000b0;C <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.72 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.07 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.99&#x02013;7.96 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.78 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.75 (d, <italic toggle="yes">J</italic> = 2.8 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.51 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.22 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.14 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.10&#x02013;6.01 (m, 1H,N-CH<sub>2</sub>-C<italic toggle="yes"><underline>H</underline></italic>=CH<sub>2</sub>), 5.24 (d, <italic toggle="yes">J</italic><sub>cis</sub> = 12.00 Hz, 1H, N-CH<sub>2</sub>-CH=C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>), 4.92 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 4.87 (d, <italic toggle="yes">J<sub>trans</sub></italic> = 16.00 Hz,1H, N-CH<sub>2</sub>CH=C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 4.82 (d, <italic toggle="yes">J</italic> = 4.6 Hz, 2H, N-C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>-CH=CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 193.30, 152.02, 148.91, 136.41, 134.81, 133.02, 132.35, 130.92, 128.36, 126.13, 125.52, 122.87, 121.27, 120.75, 117.21, 112.32, 101.96, 48.02, 41.30; anal. calcd. for C<sub>21</sub>H<sub>17</sub>BrN<sub>4</sub>OS (453.35): C, 55.64; H, 3.78; N, 12.36; S, 7.07, found: C, 55.89; H, 3.91; N, 12.50; S, 7.23.</p></sec><sec><title>2-((4-Allyl-5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(4-chlorophenyl)ethenone (<bold>6e</bold>)</title><p>Yellow crystals in (0.120 g, 63% yield); m.p 155&#x02013;157 &#x000b0;C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.75 (s, 1H, indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.08&#x02013;8.03 (m, 3H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.77 (t, J = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.65 (d, 2H, <italic toggle="yes">J=</italic> 8.00 Hz, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.51 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Indole-<italic toggle="yes"><underline>H</underline></italic>), 7.22 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.14 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Indole-C<italic toggle="yes"><underline>H</underline></italic>), 6.10&#x02013;6.01 (m, 1H, N-CH<sub>2</sub>C<italic toggle="yes"><underline>H</underline></italic>=CH<sub>2</sub>), 5.25 (d, <italic toggle="yes">J</italic><sub>cis</sub> = 12.00 Hz, 1H, N-CH<sub>2</sub>-CH=C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 4.94 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>), 4.90 (d, <italic toggle="yes">J<sub>trans</sub></italic> = 16.00 Hz,1H, N-CH<sub>2</sub>CH=C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 4.82 (d, <italic toggle="yes">J</italic> = 4.6 Hz, 2H, N-C<italic toggle="yes"><underline>H</underline></italic><underline>2</underline>-CH=CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 193.00, 151.89, 149.25, 139.17, 136.41, 134.45, 132.85, 130.85, 129.43, 126.00, 125.91, 122.96, 121.13, 120.86, 117.34, 112.40, 101.41, 46.87, 41.32; anal. calcd. for C<sub>21</sub>H<sub>17</sub>ClN<sub>4</sub>OS (408.90): C, 61.68; H, 4.19; N, 13.70; S, 7.84 found: C, 61.90; H, 4.37; N, 13.94; S, 7.95.</p></sec><sec><title>2-((5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4-phenyl-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-phenylethanone (<bold>6f</bold>)</title><p>Yellow crystals (0.100 g, 49% yield); m.p 230&#x02013;233<sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.39 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.16 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Pyrrole-C<italic toggle="yes"><underline>H</underline></italic>), 8.05&#x02013;8.03 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.71&#x02013;7.68 (m, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.65 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.64 (d, <italic toggle="yes">J</italic> = 8.00,1H, Ar-<italic toggle="yes"><underline>H</underline></italic>) 7.57 (t, <italic toggle="yes">J</italic> = 8.00, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.52&#x02013;7.50 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.41 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.17 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.11 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.50 (d, <italic toggle="yes">J</italic> = 5 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 4.91 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 192.45, 152.00, 150.27, 136.03, 135.81, 134.69, 134.22, 130.88, 130.76, 129.32, 128.91, 128.50, 125.75, 124.82, 122.94, 121.63, 120.83, 112.28, 102.32, 40.72; anal. calcd. for C<sub>24</sub>H<sub>18</sub>N<sub>4</sub>OS (410.49): C, 70.22; H, 4.42; N, 13.65; S, 7.81; found: C, 70.43; H, 4.56; N, 13.91; S, 7.89.</p></sec><sec><title>2-((5-(1<italic toggle="yes">H</italic>-Indol-3-yl)-4-phenyl-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(4-methoxyphenyl) Ethenone (<bold>6g</bold>)</title><p>Yellow crystals in (0.141g, 62% yield); m.p 236&#x02013;239 <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.38 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.16 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 8.01 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.66&#x02013;7.63 (m, 3H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.51&#x02013;7.49 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.40 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.18 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.13 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.08 (d, <italic toggle="yes">J</italic> = 8.00 Hz,2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.49 (d, <italic toggle="yes">J</italic> = 3.5 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 4.85 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 3.87 (s, 3H, OC<italic toggle="yes"><underline>H</underline></italic><sub>3</sub>); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 187.90, 164.06, 151.97, 147.24, 136.03, 134.71, 131.32, 130.86, 130.74, 128.64, 128.51, 125.75, 124.81, 122.94, 121.63, 120.83, 114.54, 112.27, 102.34, 56.12, 40.57; anal. calcd. for C<sub>25</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>S (440.52): C, 68.16; H, 4.58; N, 12.72; S, 7.28, found: C, 68.40; H, 4.67; N, 12.98; S, 7.40.</p></sec><sec><title>2-((5-(1<italic toggle="yes">H</italic>-Indol-3-yl)-4-phenyl-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(<italic toggle="yes">p</italic>-tolyl)ethenone (<bold>6h</bold>)</title><p>Yellow crystals (0.100 g, 53% yield); m.p 235&#x02013;239 <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.37 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.15 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.93 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.67&#x02013;7.62 (m, 3H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.53&#x02013;7.50 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.41&#x02013;7.37 (m, 3H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.17 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.12 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.49 (d, <italic toggle="yes">J</italic> = 3.5 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 4.87 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 2.41 (s, 3H, C<italic toggle="yes"><underline>H</underline></italic><underline><sub>3</sub></underline>); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 193.24, 151.97, 149.52, 144.76, 136.02, 134.69, 133.30, 130.87, 130.76, 129.68, 129.86, 128.50, 125.74, 124.82, 122.94, 121.62, 120.83, 112.27, 102.32, 40.69, 21.70; anal. calcd. for C<sub>25</sub>H<sub>20</sub>N<sub>4</sub>OS (424.52): C, 70.73; H, 4.75; N, 13.20; S, 7.55, found: C, 70.98; H, 4.89; N, 13.47; S, 7.62.</p></sec><sec><title>2-((5-(1<italic toggle="yes">H</italic>-Indol-3-yl)-4-phenyl-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(4-bromophenyl) Ethenone (<bold>6i</bold>)</title><p>Yellow crystals in (0.159 g, 63% yield); m.p 229&#x02013;232 <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.37 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.15 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.97(d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.79 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.66&#x02013;7.63 (m, 3H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.53&#x02013;7.50 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.40 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.18 (t, <italic toggle="yes">J</italic> = 8.00, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.13 (t, <italic toggle="yes">J</italic> = 8.00, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.49 (d, <italic toggle="yes">J</italic> = 3.5 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 4.87 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 193.11, 152.03, 149.34, 136.03, 134.85, 134.66, 132.38, 130.93, 130.89, 130.76, 128.48, 128.33, 125.73, 124.84, 122.94, 121.62, 120.83, 111.59, 101.63, 40.59; anal. calcd. for C<sub>24</sub>H<sub>17</sub>BrN<sub>5</sub>OS (489.39): C, 58.90; H, 3.50; Br, 16.33; N, 11.45; S, 6.55, found: C, 59.12; H, 3.66; N, 11.72; S, 6.64.</p></sec><sec><title>2-((5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4-phenyl-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(4-chlorophenyl) Ethenone (<bold>6j</bold>)</title><p>Yellow crystals in (0.078 g, 34% yield); m.p 234&#x02013;237 <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.37 (s, 1H, indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.15 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 8.05 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.66&#x02013;7.64 (m, 5H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.52&#x02013;7.50 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.40 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.17 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.12 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.49 (d, <italic toggle="yes">J</italic> = 3.5 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 4.87 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 192.35, 152.03, 149.35, 139.12, 136.02, 134.65, 134.52, 130.89, 130.85, 130.76, 129.43, 127.57, 125.72, 124.84, 122.95, 121.61, 120.84, 112.27, 101.92, 40.56; anal. calcd. for C<sub>24</sub>H<sub>17</sub>ClN<sub>4</sub>OS (444.94): C, 64.79; H, 3.85; Cl, 7.97; N, 12.59; S, 7.21, found: C, 65.02; H, 4.01; N, 12.80; S, 7.35.</p></sec></sec><sec id="sec3dot1dot2-pharmaceuticals-18-00275"><title>3.1.2. General Procedure for the Synthesis of (Z)-2-((5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4-allyl/phenyl-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-phenylethanone Oxime Derivatives (<bold>7a</bold>&#x02013;<bold>j</bold>)</title><p>A mixture of the appropriate ketone <bold>6a</bold>&#x02013;<bold>j</bold> (1.00 mol), hydroxylamine hydrochloride (5.00 mol), and anhydrous sodium acetate (5.00 mol) in absolute ethanol (30 mL) was heated under reflux at a temperature of 50&#x02013;70 &#x000b0;C for 2&#x02013;8 h. The reaction mixture was filtered to separate hydroxylamine hydrochloride and anhydrous sodium acetate. The filtrate was evaporated, and the separated solid was washed with a diluted ammonia solution (10%), dried, and crystallized from aqueous ethanol, affording the target compounds <bold>7a</bold>&#x02013;<bold>j</bold>.</p><sec><title>(Z)-2-((4-Allyl-5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-phenylethanone Oxime (<bold>7a</bold>)</title><p>Yellow crystals in (0.085 g, 48% yield); m.p 203&#x02013;209 &#x000b0;C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.81 (s, 1H, O<italic toggle="yes"><underline>H</underline></italic>), 11.69 (s, 1H, indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.07 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.71&#x02013;7.69 (m, 3H, 2Ar-<italic toggle="yes"><underline>H</underline>+</italic>CO-C<italic toggle="yes"><underline>H</underline></italic>=CH), 7.49 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.42&#x02013;7.34 (m, 3H, 2Ar-<italic toggle="yes"><underline>H</underline></italic>+CO-CH=C<italic toggle="yes"><underline>H</underline></italic>), 7.23 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.16 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.00&#x02013;5.91 (m, 1H, N-CH<sub>2</sub>-C<italic toggle="yes"><underline>H</underline></italic>=CH<sub>2</sub>), 5.13 (d, <italic toggle="yes">J</italic><sub>cis</sub> = 12.00 Hz, 1H, N-CH<sub>2</sub>-CH=C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>), 4.74 (<italic toggle="yes">J<sub>trans</sub></italic> = 16.00 Hz,1 H, N-CH<sub>2</sub>CH=C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 4.69 (d, <italic toggle="yes">J</italic> = 4.6 Hz, 2H, N-C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>-CH=CH<sub>2</sub>), 4.43 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): <sup>13</sup>C NMR 152.26, 151.67, 148.50, 135.90, 134.41, 132.67, 129.10, 128.50, 125.89, 125.67, 125.14, 122.38, 120.89, 120.26, 116.53, 111.82, 101.58, 46.52, 25.94; anal. calcd. for C<sub>21</sub>H<sub>19</sub>N<sub>5</sub>OS (389.47): C, 64.76; H, 4.92; N, 17.98; S, 8.23, found: C, 64.52; H, 5.07; N, 18.15; S, 8.40.</p></sec><sec><title>2-((4-allyl-5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(4-methoxyphenyl) Ethanone Oxime (<bold>7b</bold>)</title><p>Yellow crystals in (0.120 g, 47% yield); m.p 191&#x02013;194 &#x000b0;C <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.77 (s, 1H, -O<italic toggle="yes"><underline>H</underline></italic>), 11.63 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.08 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 8.69 (s, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.61 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.50 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.22 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.15 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.94 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.00&#x02013;5.92 (m, 1H, N-CH<sub>2</sub>-C<italic toggle="yes"><underline>H</underline></italic>=CH<sub>2</sub>), 5.14 (d, <italic toggle="yes">J</italic><sub>cis</sub> = 12.00 Hz, 1H, N-CH<sub>2</sub>-CH=C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>), 4.71 (d, <italic toggle="yes">J<sub>trans</sub></italic> = 16.00 Hz, N-CH<sub>2</sub>CH=C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 4.68 (d, <italic toggle="yes">J</italic> = 2.30 Hz, 2H, N-C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>-CH=CH<sub>2</sub>), 4.39 (s, 2H, S-<italic toggle="yes"><underline>CH</underline></italic><underline><sub>2</sub></underline>), 3.71 (s, 3H, O-CH<sub>3</sub>); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 160.44, 152.33, 152.11, 149.06, 136.38, 133.18, 127.72, 127.20, 126.14, 125.58, 122.83, 121.34, 120.70, 116.96, 114.37, 112.31, 101.08, 55.61, 46.57, 26.77.; anal. calcd. for C<sub>22</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S (419.50): C, 62.99; H, 5.05; N, 16.69; S, 7.64, found: C, 63.18; H, 5.42; N, 14.67; S, 8.34.</p></sec><sec><title>(Z)-2-((4-allyl-5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(<italic toggle="yes">p</italic>-tolyl)ethanone Oxime (<bold>7c</bold>)</title><p>Yellowish white crystals (0.750 g, 70% yield); m.p 128&#x02013;204 &#x000b0;C <sup>1</sup>H NMR (400 MHz, DMSO) &#x003b4; 11.98 (s, 1H, O<italic toggle="yes"><underline>H</underline></italic>), 11.72 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.08 (d, <italic toggle="yes">J</italic> = 8 Hz, 1H, Pyrrole-C<italic toggle="yes"><underline>H</underline></italic>), 7.69 (d, <italic toggle="yes">J</italic> = 2.8 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.58 (d, <italic toggle="yes">J</italic> = 8 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.52 (d, <italic toggle="yes">J</italic> = 8 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.24&#x02013;7.20 (t, <italic toggle="yes">J</italic> = 8 Hz, 1H, Indole-C<italic toggle="yes"><underline>H</underline></italic>),7.18&#x02013;7.16 (d, <italic toggle="yes">J</italic> = 8 Hz, 2H, Ar-<italic toggle="yes"><underline>H)</underline></italic>, 7.17&#x02013;7.12 (t, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, Indole-C<italic toggle="yes"><underline>H</underline></italic>), 6.00&#x02013;5.91 (m, 1H, N-CH2-C<italic toggle="yes"><underline>H</underline></italic>=CH2), 5.15 (d, <italic toggle="yes">J</italic><sub>cis</sub> = 12 Hz, 1H, N-CH2-CH=C<italic toggle="yes"><underline>H</underline></italic><underline>2</underline>), 4.73 (d, <italic toggle="yes">J<sub>trans</sub></italic> = 16 Hz,1H, N-CH<sub>2</sub>CH=C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 4.68 (d, J = 4.6 Hz, 2H, N-C<italic toggle="yes"><underline>H</underline></italic><underline>2</underline>-CH=CH<sub>2</sub>), 4.41 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 2.24 (s, 3H,C<italic toggle="yes"><underline>H</underline></italic><underline><sub>3</sub></underline>); <sup>13</sup>C NMR (101 MHz, DMSO) &#x003b4; 152.63, 152.13, 149.00, 139.09, 136.40, 133.15, 132.04, 129.52, 126.24, 126.13, 125.57, 122.82, 121.30, 120.70, 116.95, 112.35, 101.96, 47.27, 26.64, 21.19; anal. calcd. for C<sub>22</sub>H<sub>21</sub>N<sub>5</sub>OS (403.15): C, 65.49; H, 5.25; N, 17.36; O, 3.97; S, 7.95, found: C, 65.32; H, 5.43; N, 17.52; S, 8.09.</p></sec><sec><title>(Z)-2-((4-allyl-5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(4-bromophenyl) Ethanone Oxime (<bold>7d</bold>)</title><p>Yellowish white crystals in (0.131 g, 55% yield); m.p 217&#x02013;222 <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.98 (s, 1H, O<italic toggle="yes"><underline>H</underline></italic>), 11.72 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.09 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.72 (d, <italic toggle="yes">J</italic> = 2.8 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.66 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.59 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.52&#x02013;7.49 (m, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.23 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.16 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>) 6.01&#x02013;5.92 (m, 1H, N-CH<sub>2</sub>-C<italic toggle="yes"><underline>H</underline></italic>=CH<sub>2</sub>), 5.16 (d, <italic toggle="yes">J</italic><sub>cis</sub> = 12.00 Hz, 1H, N-CH<sub>2</sub>-CH=C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>), 4.76 (d, <italic toggle="yes">J<sub>trans</sub></italic> = 16.00 Hz,1H, N-CH<sub>2</sub>CH=C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 4.72 (d, <italic toggle="yes">J</italic> = 4.6 Hz, 2H, N-C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>-CH=CH<sub>2</sub>), 4.43 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 152.18, 152.03, 148.70, 136.40, 134.11, 133.13, 131.90, 128.42, 126.16, 125.64, 122.99, 122.88, 121.34, 120.78, 117.03, 112.31, 102.03, 46.63, 27.02; anal. calcd. for C<sub>21</sub>H<sub>18</sub>BrN<sub>5</sub>OS (468.37): C, 53.85; H, 3.87; N, 14.95; S, 6.85, found: C, 54.03; H, 4.03; N, 15.17; S, 6.98.</p></sec><sec><title>(Z)-2-((4-allyl-5-(1<italic toggle="yes">H</italic>-indol-3-yl)-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(4-chlorophenyl) Ethanone Oxime (<bold>7e</bold>)</title><p>Yellow crystals in (0.048 g, 43% yield); m.p 163&#x02013;167 &#x000b0;C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.98 (s, 1H, O<italic toggle="yes"><underline>H</underline></italic>), 11.72 (s, 1H, N<italic toggle="yes"><underline>H</underline></italic>), 8.09 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, pyrrole-C<italic toggle="yes"><underline>H</underline></italic>), 7.74&#x02013;7.72 (m, 3H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.51 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.45 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.23 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.16 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.02&#x02013;5.92 (m, 1H, N-CH<sub>2</sub>-C<italic toggle="yes"><underline>H</underline></italic>=CH<sub>2</sub>), 5.16 (d, <italic toggle="yes">J</italic><sub>cis</sub> = 8.00 Hz, 1H, N-CH<sub>2</sub>-CH=C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>), 4.74 (d, <italic toggle="yes">J<sub>trans</sub></italic> = 16.00 Hz,1H, N-CH<sub>2</sub>CH=C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 4.72 (d, <italic toggle="yes">J</italic> = 4.6 Hz, 2H, N-C<italic toggle="yes"><underline>H</underline></italic><underline><sub>2</sub></underline>-CH=CH<sub>2</sub>), 4.43 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 152.18, 151.94, 148.71, 136.39, 134.29, 133.73, 133.13, 129.40, 128.15, 126.14, 125.64, 122.88, 121.34, 120.77, 117.01, 112.31, 102.02, 47.65, 27.46; anal. calcd. for C<sub>21</sub>H<sub>18</sub>ClN<sub>5</sub>OS (423.92): C, 59.50; H, 4.28; N, 16.52; S, 7.56, found: C, 59.72; H, 4.40; N, 16.78; S, 7.67.</p></sec><sec><title>(Z)-2-((5-(1<italic toggle="yes">H</italic>-Indol-3-yl)-4-phenyl-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-phenylethanone Oxime (<bold>7f</bold>)</title><p>Yellow crystals in (0.040 g, 42% yield); m.p 260&#x02013;267 &#x000b0;C <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.79 (s,1H, O<italic toggle="yes"><underline>H</underline></italic>), 11.38 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.22 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Pyrrole-C<italic toggle="yes"><underline>H</underline></italic>), 7.68&#x02013;7.66 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.63&#x02013;7.58 (m, 3H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.45&#x02013;7.43 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.42&#x02013;7.41 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.40&#x02013;7.38 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.20 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.14 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.44 (s, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 4.39 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 152.45, 152.39, 149.26, 136.03, 134.85, 134.81, 130.78, 130.63, 129.59, 128.98, 128.59, 126.37, 125.78, 124.84, 122.96, 121.76, 120.85, 113.01, 102.43, 28.10; anal. calcd. for C<sub>24</sub>H<sub>19</sub>N<sub>5</sub>OS (425.51): C, 67.74; H, 4.50; N, 16.46; S, 7.54, found: C, 68.01; H, 4.67; N, 16.72; S, 7.61.</p></sec><sec><title>(Z)-2-((5-(1<italic toggle="yes">H</italic>-Indol-3-yl)-4-phenyl-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(4-methoxyphenyl) Ethanone Oxime (<bold>7g</bold>)</title><p>Yellow crystals in (0.076 g, 65% yield); m.p 202&#x02013;206 &#x000b0;C <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.56 (s,1H, O<italic toggle="yes"><underline>H</underline></italic>), 11.42 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.22 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Pyrrole-C<italic toggle="yes"><underline>H</underline></italic>), 7.63&#x02013;7.58 (m, 5H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.45&#x02013; 7.43 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.41 (d, <italic toggle="yes">J</italic> = 8.00 Hz 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.20 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.14 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.95 (d, <italic toggle="yes">J</italic> = 8.00 Hz,2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.49 (d, <italic toggle="yes">J</italic> = 3.00Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 4.37 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 3.76 (s, 3H, OC<italic toggle="yes"><underline>H</underline></italic><sub>3</sub>); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 160.50, 152.34, 152.04, 149.42, 136.02, 134.79, 130.78, 130.35, 128.58, 127.76, 126.77, 125.78, 124.84, 122.95, 121.74, 120.84, 114.41, 112.27, 101.40, 55.66, 26.61; anal. calcd. for C<sub>25</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S (455.53): C, 65.92; H, 4.65; N, 15.37; S, 7.04, found: C, 65.71; H, 4.82; N, 15.54; S, 7.18.</p></sec><sec><title>(Z)-2-((5-(1<italic toggle="yes">H</italic>-Indol-3-yl)-4-phenyl-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(<italic toggle="yes">p</italic>-tolyl)ethanone Oxime (<bold>7h</bold>)</title><p>Yellow crystals in (0.035 g, 25% yield); m.p 239&#x02013;241 &#x000b0;C <sup>1</sup>H NMR (500 MHz, DMSO) &#x003b4; 11.66 (s,1H, O<italic toggle="yes"><underline>H</underline></italic>), 11.37 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.22 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Pyrrole-C<italic toggle="yes"><underline>H</underline></italic>), 7.63&#x02013;7.59 (m, 3H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.55 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.45&#x02013;7.43 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.41 (d, <italic toggle="yes">J</italic> = 8.00 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.21&#x02013;7.19 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.17&#x02013;7.13 (m. 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>) 6.44 (d, <italic toggle="yes">J</italic> = 2.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 4.37 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>), 2.31 (s, 3H, C<italic toggle="yes"><underline>H</underline></italic><underline><sub>3</sub></underline>); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 152.35, 152.31, 149.33, 138.77, 136.02, 134.80, 132.04, 130.77, 130.63, 129.56, 128.59, 126.28, 125.78, 124.84, 122.95, 121.74, 120.45, 112.26, 102.43, 26.22, 23.18; anal. calcd. for C<sub>25</sub>H<sub>21</sub>N<sub>5</sub>OS (439.53): C, 68.32; H, 4.82; N, 15.93; S, 7.30, found: C, 68.50; H, 4.97; N, 16.17; S, 7.26.</p></sec><sec><title>(Z)-2-((5-(1<italic toggle="yes">H</italic>-Indol-3-yl)-4-phenyl-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(4-bromophenyl) Ethanone Oxime (<bold>7i</bold>)</title><p>Yellow crystals in (0.070 g, 66% yield); m.p 242&#x02013;244 &#x000b0;C <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.90 (s,1H, O<italic toggle="yes"><underline>H</underline></italic>), 11.38 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.21 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Pyrrole-C<italic toggle="yes"><underline>H</underline></italic>), 7.65&#x02013;7.59 (m, 7H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.45&#x02013;7.41 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.40 (d, J = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.18 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.14 (t, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.44 (d, <italic toggle="yes">J</italic> = 3.5 Hz, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 4.35 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>); <sup>13</sup>C NMR (126 MHz, DMSO) &#x003b4; 152.43, 151.68, 148.88, 136.01, 134.80, 134.08, 132.43, 131.92, 130.78, 130.63, 128.58, 128.45, 125.77, 124.87, 122.97, 121.74, 120.86, 113.28, 102.66, 25.49; anal. calcd. for C<sub>24</sub>H<sub>18</sub>BrN<sub>5</sub>OS (504.40): C, 57.15; H, 3.60; Br, 15.84; N, 13.88; S, 6.36, found: C, 57.38; H, 3.74; N, 14.12; S, 6.45.</p></sec><sec><title>(Z)-2-((5-(1<italic toggle="yes">H</italic>-Indol-3-yl)-4-phenyl-4<italic toggle="yes">H</italic>-1,2,4-triazol-3-yl)thio)-1-(4-chlorophenyl) Ethanone Oxime (<bold>7j</bold>)</title><p>Yellow crystals in (0.70 g, 66% yield); m.p 248&#x02013;250 &#x000b0;C <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 11.90 (s, 1H, O<italic toggle="yes"><underline>H</underline></italic>), 11.40 (s, 1H, Indole-N<italic toggle="yes"><underline>H</underline></italic>), 8.24 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 1H, Pyrrole-C<italic toggle="yes"><underline>H</underline></italic>), 7.71 (d, <italic toggle="yes">J</italic> = 8.00 Hz, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.63&#x02013;7.61 (m, 3H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.48&#x02013;7.42 (m, 5H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 7.26&#x02013;7.14 (m, 2H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 6.47 (s, 1H, Ar-<italic toggle="yes"><underline>H</underline></italic>), 4.38 (s, 2H, S-C<italic toggle="yes"><underline>H</underline></italic><sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 152.47, 151.67, 149.04, 136.06, 134.78, 134.31, 133.70, 130.93, 130.78, 130.62, 129.00, 128.55, 128.18, 125.80, 124.93, 123.00, 121.75, 120.91, 112.29, 102.41, 28.1; anal. calcd. for C<sub>24</sub>H<sub>18</sub>ClN<sub>5</sub>OS (459.95): C, 62.67; H, 3.94; N, 15.23; S, 6.97, found: C, 62.51; H, 4.12; N, 15.45; S, 7.08.</p></sec></sec></sec><sec id="sec3dot2-pharmaceuticals-18-00275"><title>3.2. Biology</title><sec id="sec3dot2dot1-pharmaceuticals-18-00275"><title>3.2.1. NCI&#x02019;s In Vitro Study of Antiproliferative Activity</title><p>The NCI anticancer screening process has been thoroughly detailed [<xref rid="B43-pharmaceuticals-18-00275" ref-type="bibr">43</xref>,<xref rid="B47-pharmaceuticals-18-00275" ref-type="bibr">47</xref>]. The Drug Evaluation Branch of the National Cancer Institute in Bethesda, MA, USA, established the procedure and conducted the anticancer assay on 60 human tumor cell lines from nine neoplastic cancers [<xref rid="B43-pharmaceuticals-18-00275" ref-type="bibr">43</xref>,<xref rid="B47-pharmaceuticals-18-00275" ref-type="bibr">47</xref>].</p></sec><sec id="sec3dot2dot2-pharmaceuticals-18-00275"><title>3.2.2. Tubulin Polymerization Assay</title><p>The substances&#x02019; effects on tubulin polymerization were examined using the Tubulin Polymerization Assay Kit (Cytoskeleton Inc., Denver, CO, USA) according to the supplier&#x02019;s instructions, with details described in <xref rid="app2-pharmaceuticals-18-00275" ref-type="app">Appendix A</xref>. [<xref rid="B34-pharmaceuticals-18-00275" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-18-00275" ref-type="bibr">35</xref>].</p></sec><sec id="sec3dot2dot3-pharmaceuticals-18-00275"><title>3.2.3. Cell Cycle Analysis and Apoptosis Detection</title><p>The MDA-MB231 breast cancer cell line was used for cell cycle study and apoptosis detection. The assay was performed as previously documented [<xref rid="B52-pharmaceuticals-18-00275" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceuticals-18-00275" ref-type="bibr">53</xref>] (<xref rid="app2-pharmaceuticals-18-00275" ref-type="app">Appendix A</xref>).</p></sec></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceuticals-18-00275"><title>4. Conclusions</title><p>We synthesized and evaluated a novel class of indole/1,2,4-triazole hybrids for their anticancer potential. NCI selected compounds <bold>6h</bold>, <bold>7h</bold>, <bold>7i</bold>, and <bold>7j</bold> for a five-dose assay, which showed selectivity ratios ranging from 0.52 to 2.29 at the GI<sub>50</sub> values. Compounds <bold>7i</bold> and <bold>7j</bold> demonstrated the greatest efficacy among all of the novel compounds in inhibiting cancer cell proliferation, and they also showed substantial inhibitory activity against tubulin. The NO-releasing oxime moiety in compounds <bold>7a</bold>&#x02013;<bold>j</bold> made them more effective against cancer than their precursor ketones <bold>6a</bold>&#x02013;<bold>j</bold> in all of the tested cancer cell lines. Compound <bold>7i</bold> demonstrated significant cellular accumulation during the G1 phase, affirming its capacity to induce cell cycle arrest at this stage. Compound <bold>7i</bold> effectively induced substantial amounts of apoptosis, with a necrosis percentage of 3.88. Compounds <bold>7i</bold> and <bold>7j</bold> displayed significant antiproliferative activity as tubulin inhibitors and may serve as lead compounds for further optimization and comprehensive biological tests.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was funded by the Researchers Supporting Project Number (RSPD2025R603) at King Saud University, Riyadh, Saudi Arabia. The authors also acknowledge support from the KIT-Publication Fund of the Karlsruhe Institute of Technology.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceuticals-18-00275"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/ph18020275/s1">https://www.mdpi.com/article/10.3390/ph18020275/s1</uri>, All supplementary data to this article were submitted in a separate file.</p><supplementary-material id="pharmaceuticals-18-00275-s001" position="float" content-type="local-data"><media xlink:href="pharmaceuticals-18-00275-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>E.M.: Formal Analysis, Methodology, Software, and Writing&#x02014;original draft. D.A.: Supervision, Investigation, Validation, Visualization, and Writing&#x02014;original draft. A.F.M.: Methodology and Writing&#x02014;original draft. Z.M.A. and S.B.: Writing&#x02014;original draft. A.M.H.: Supervision, Investigation, Validation, Visualization, and Writing&#x02014;review and editing. B.G.M.Y.: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Visualization, Writing&#x02014;original draft, and Writing&#x02014;review and editing. M.A.-A.: Supervision, Investigation, Validation, Visualization, and Writing&#x02014;review and editing. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data can be obtained on request from the authors.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors state that they have no known competing financial interests or relationships that could have affected the work described in this study.</p></notes><app-group><app id="app2-pharmaceuticals-18-00275"><title>Appendix A</title><p>
<bold>General Details:</bold>
</p><p>Chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA), Kanto Chemical (Tokyo, Japan), Nacalai tesque (Kyoto Japan), Tokyo Chemical Industry (Tokyo, Japan), and Wako (Osaka, Japan). Thin layer chromatography (TLC) was performed on precoated plates [Merck Millipore (Burlington, MA, USA), TLC sheets silica 60 F<sub>254</sub>, and Fuji Silysia Chemical Ltd. (Kasugai, Japan) TLC sheets Chromatorex NH silica]. Chromatography was carried out on Silica Gel 60 N (40&#x02013;100 mesh) (Fuji Silysia Chemical Ltd., Greenville, NC, USA). NMR spectra BRUKER AVANCE 600 MHz (Karlsruhe, Germany) were referenced to TMS. Infra-red spectra were recorded on a JASCO FT/IR-410 or JEOL JIR-6500 W/PerkinElmer Frontier (Gifu, Japan). The samples were prepared as KBr discs or Film or using the ATR method.</p><p>
<bold>Tubulin polymerization assay</bold>
</p><p>The activity of compounds on tubulin polymerization was investigated using the Tubulin Polymerization Assay Kit (Cytoskeleton Inc., Denver, CO, USA), which works via fluorescent reporter enhancement. The fluorescence of compounds (dissolved in DMSO at 5 and 25 &#x000b5;M concentration) was recorded in triplicates using FLUO star OPTIMA. Docetaxel and vincristine (Apoteket AB, Stockholm, Sweden) served as positive stabilizing and destabilizing controls. Both were used at a 3 &#x000b5;M concentration in PBS.</p></app></app-group><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00275"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Ruddon</surname><given-names>R.W.</given-names></name>
</person-group><source>Cancer Biology</source><publisher-name>Oxford University Press</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>2007</year></element-citation></ref><ref id="B2-pharmaceuticals-18-00275"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiramongkol</surname><given-names>Y.</given-names></name>
<name><surname>Lam</surname><given-names>E.W.-F.</given-names></name>
</person-group><article-title>Foxo transcription factor family in cancer and metastasis</article-title><source>Cancer Metastasis Rev.</source><year>2020</year><volume>39</volume><fpage>681</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">32372224</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00275"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mattiuzzi</surname><given-names>C.</given-names></name>
<name><surname>Lippi</surname><given-names>G.</given-names></name>
</person-group><article-title>Current cancer epidemiology</article-title><source>J. Epidemiol. Glob. Health</source><year>2019</year><volume>9</volume><fpage>217</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.2991/jegh.k.191008.001</pub-id><pub-id pub-id-type="pmid">31854162</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-18-00275"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagai</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>Y.H.</given-names></name>
</person-group><article-title>Cancer prevention from the perspective of global cancer burden patterns</article-title><source>J. Thorac. Dis.</source><year>2017</year><volume>9</volume><fpage>448</fpage><pub-id pub-id-type="doi">10.21037/jtd.2017.02.75</pub-id><pub-id pub-id-type="pmid">28449441</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-18-00275"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siegel</surname><given-names>R.L.</given-names></name>
<name><surname>Miller</surname><given-names>K.D.</given-names></name>
<name><surname>Jemal</surname><given-names>A.</given-names></name>
</person-group><article-title>Cancer statistics, 2019</article-title><source>CA Cancer J. Clin.</source><year>2019</year><volume>69</volume><fpage>7</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.3322/caac.21551</pub-id><pub-id pub-id-type="pmid">30620402</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00275"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Debela</surname><given-names>D.T.</given-names></name>
<name><surname>Muzazu</surname><given-names>S.G.</given-names></name>
<name><surname>Heraro</surname><given-names>K.D.</given-names></name>
<name><surname>Ndalama</surname><given-names>M.T.</given-names></name>
<name><surname>Mesele</surname><given-names>B.W.</given-names></name>
<name><surname>Haile</surname><given-names>D.C.</given-names></name>
<name><surname>Kitui</surname><given-names>S.K.</given-names></name>
<name><surname>Manyazewal</surname><given-names>T.</given-names></name>
</person-group><article-title>New approaches and procedures for cancer treatment: Current perspectives</article-title><source>SAGE Open Med.</source><year>2021</year><volume>9</volume><fpage>20503121211034366</fpage><pub-id pub-id-type="doi">10.1177/20503121211034366</pub-id><pub-id pub-id-type="pmid">34408877</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00275"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ward</surname><given-names>R.A.</given-names></name>
<name><surname>Fawell</surname><given-names>S.</given-names></name>
<name><surname>Floc&#x02019;h</surname><given-names>N.</given-names></name>
<name><surname>Flemington</surname><given-names>V.</given-names></name>
<name><surname>McKerrecher</surname><given-names>D.</given-names></name>
<name><surname>Smith</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Challenges and opportunities in cancer drug resistance</article-title><source>Chem. Rev.</source><year>2020</year><volume>121</volume><fpage>3297</fpage><lpage>3351</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.0c00383</pub-id><pub-id pub-id-type="pmid">32692162</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00275"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Tan</surname><given-names>L.</given-names></name>
<name><surname>Siu</surname><given-names>K.T.H.</given-names></name>
<name><surname>Guan</surname><given-names>X.-Y.</given-names></name>
</person-group><article-title>Exploring treatment options in cancer: Tumor treatment strategies</article-title><source>Signal Transduct. Target. Ther.</source><year>2024</year><volume>9</volume><fpage>175</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-01856-7</pub-id><pub-id pub-id-type="pmid">39013849</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00275"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sebastian</surname><given-names>J.</given-names></name>
<name><surname>Rathinasamy</surname><given-names>K.</given-names></name>
</person-group><article-title>Microtubules and cell division: Potential pharmacological targets in cancer therapy</article-title><source>Curr. Drug Targets</source><year>2023</year><volume>24</volume><fpage>889</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.2174/1389450124666230731094837</pub-id><pub-id pub-id-type="pmid">37519203</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00275"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Peng</surname><given-names>Y.</given-names></name>
<name><surname>Tao</surname><given-names>X.</given-names></name>
<name><surname>Ding</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>R.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Zuo</surname><given-names>W.</given-names></name>
</person-group><article-title>Microtubule organization is essential for maintaining cellular morphology and function</article-title><source>Oxidative Med. Cell. Longev.</source><year>2022</year><volume>2022</volume><fpage>1623181</fpage><pub-id pub-id-type="doi">10.1155/2022/1623181</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-18-00275"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Janke</surname><given-names>C.</given-names></name>
<name><surname>Magiera</surname><given-names>M.M.</given-names></name>
</person-group><article-title>The tubulin code and its role in controlling microtubule properties and functions</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2020</year><volume>21</volume><fpage>307</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1038/s41580-020-0214-3</pub-id><pub-id pub-id-type="pmid">32107477</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-18-00275"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baytas</surname><given-names>S.N.</given-names></name>
</person-group><article-title>Recent advances in combretastatin a-4 inspired inhibitors of tubulin polymerization: An update</article-title><source>Curr. Med. Chem.</source><year>2022</year><volume>29</volume><fpage>3557</fpage><lpage>3585</lpage><pub-id pub-id-type="doi">10.2174/1871526522666220105114437</pub-id><pub-id pub-id-type="pmid">34986762</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00275"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Guo</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Wu</surname><given-names>L.</given-names></name>
</person-group><article-title>Dual-functional antitumor conjugates improving the anti-metastasis effect of combretastatin a4 by targeting tubulin polymerization and matrix metalloproteinases</article-title><source>Eur. J. Med. Chem.</source><year>2022</year><volume>238</volume><fpage>114439</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2022.114439</pub-id><pub-id pub-id-type="pmid">35551039</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-18-00275"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tron</surname><given-names>G.C.</given-names></name>
<name><surname>Pirali</surname><given-names>T.</given-names></name>
<name><surname>Sorba</surname><given-names>G.</given-names></name>
<name><surname>Pagliai</surname><given-names>F.</given-names></name>
<name><surname>Busacca</surname><given-names>S.</given-names></name>
<name><surname>Genazzani</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Medicinal chemistry of combretastatin a4: Present and future directions</article-title><source>J. Med. Chem.</source><year>2006</year><volume>49</volume><fpage>3033</fpage><lpage>3044</lpage><pub-id pub-id-type="doi">10.1021/jm0512903</pub-id><pub-id pub-id-type="pmid">16722619</pub-id>
</element-citation></ref><ref id="B15-pharmaceuticals-18-00275"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hsieh</surname><given-names>H.</given-names></name>
<name><surname>Liou</surname><given-names>J.</given-names></name>
<name><surname>Mahindroo</surname><given-names>N.</given-names></name>
</person-group><article-title>Pharmaceutical design of antimitotic agents based on combretastatins</article-title><source>Curr. Pharm. Des.</source><year>2005</year><volume>11</volume><fpage>1655</fpage><lpage>1677</lpage><pub-id pub-id-type="doi">10.2174/1381612053764751</pub-id><pub-id pub-id-type="pmid">15892667</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00275"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seddigi</surname><given-names>Z.S.</given-names></name>
<name><surname>Malik</surname><given-names>M.S.</given-names></name>
<name><surname>Saraswati</surname><given-names>A.P.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.A.</given-names></name>
<name><surname>Babalghith</surname><given-names>A.O.</given-names></name>
<name><surname>Lamfon</surname><given-names>H.A.</given-names></name>
<name><surname>Kamal</surname><given-names>A.</given-names></name>
</person-group><article-title>Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents</article-title><source>MedChemComm</source><year>2017</year><volume>8</volume><fpage>1592</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.1039/C7MD00227K</pub-id><pub-id pub-id-type="pmid">30108870</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-18-00275"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Jian</surname><given-names>X.-E.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Ma</surname><given-names>Y.-F.</given-names></name>
<name><surname>Liu</surname><given-names>Y.-X.</given-names></name>
<name><surname>You</surname><given-names>W.-W.</given-names></name>
<name><surname>Zhao</surname><given-names>P.-L.</given-names></name>
</person-group><article-title>Discovery of new indole-based 1, 2, 4-triazole derivatives as potent tubulin polymerization inhibitors with anticancer activity</article-title><source>New J. Chem.</source><year>2021</year><volume>45</volume><fpage>21869</fpage><lpage>21880</lpage><pub-id pub-id-type="doi">10.1039/D1NJ03892C</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-18-00275"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salerno</surname><given-names>S.</given-names></name>
<name><surname>Barresi</surname><given-names>E.</given-names></name>
<name><surname>Baglini</surname><given-names>E.</given-names></name>
<name><surname>Poggetti</surname><given-names>V.</given-names></name>
<name><surname>Da Settimo</surname><given-names>F.</given-names></name>
<name><surname>Taliani</surname><given-names>S.</given-names></name>
</person-group><article-title>Target-based anticancer indole derivatives for the development of anti-glioblastoma agents</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>2587</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28062587</pub-id><pub-id pub-id-type="pmid">36985576</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-18-00275"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>Z.</given-names></name>
<name><surname>Jiang</surname><given-names>Z.</given-names></name>
<name><surname>Zhu</surname><given-names>W.</given-names></name>
<name><surname>Qiao</surname><given-names>D.</given-names></name>
</person-group><article-title>Indole-based tubulin inhibitors: Binding modes and sars investigations</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>1587</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27051587</pub-id><pub-id pub-id-type="pmid">35268688</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00275"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pecnard</surname><given-names>S.</given-names></name>
<name><surname>Provot</surname><given-names>O.</given-names></name>
<name><surname>Levaique</surname><given-names>H.</given-names></name>
<name><surname>Bignon</surname><given-names>J.</given-names></name>
<name><surname>Askenatzis</surname><given-names>L.</given-names></name>
<name><surname>Saller</surname><given-names>F.</given-names></name>
<name><surname>Borgel</surname><given-names>D.</given-names></name>
<name><surname>Michallet</surname><given-names>S.</given-names></name>
<name><surname>Laisne</surname><given-names>M.-C.</given-names></name>
<name><surname>Lafanech&#x000e8;re</surname><given-names>L.</given-names></name>
</person-group><article-title>Cyclic bridged analogs of isoca-4: Design, synthesis and biological evaluation</article-title><source>Eur. J. Med. Chem.</source><year>2021</year><volume>209</volume><fpage>112873</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112873</pub-id><pub-id pub-id-type="pmid">33038796</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00275"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mustafa</surname><given-names>M.</given-names></name>
<name><surname>Abdelhamid</surname><given-names>D.</given-names></name>
<name><surname>Abdelhafez</surname><given-names>E.M.</given-names></name>
<name><surname>Ibrahim</surname><given-names>M.A.</given-names></name>
<name><surname>Gamal-Eldeen</surname><given-names>A.M.</given-names></name>
<name><surname>Aly</surname><given-names>O.M.</given-names></name>
</person-group><article-title>Synthesis, antiproliferative, anti-tubulin activity, and docking study of new 1, 2, 4-triazoles as potential combretastatin analogues</article-title><source>Eur. J. Med. Chem.</source><year>2017</year><volume>141</volume><fpage>293</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.09.063</pub-id><pub-id pub-id-type="pmid">29031074</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00275"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.-H.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Yang</surname><given-names>H.-K.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Diao</surname><given-names>P.-C.</given-names></name>
<name><surname>You</surname><given-names>W.-W.</given-names></name>
<name><surname>Zhao</surname><given-names>P.-L.</given-names></name>
</person-group><article-title>Design, synthesis, and biological evaluation of novel alkylsulfanyl-1, 2, 4-triazoles as cis-restricted combretastatin a-4 analogues</article-title><source>Eur. J. Med. Chem.</source><year>2017</year><volume>125</volume><fpage>1098</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2016.10.051</pub-id><pub-id pub-id-type="pmid">27810596</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-18-00275"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>P.</given-names></name>
<name><surname>Huo</surname><given-names>X.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Diao</surname><given-names>P.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Zheng</surname><given-names>S.</given-names></name>
<name><surname>Hu</surname><given-names>M.</given-names></name>
<name><surname>You</surname><given-names>W.</given-names></name>
</person-group><article-title>Development of triazolothiadiazine derivatives as highly potent tubulin polymerization inhibitors: Structure-activity relationship, in vitro and in vivo study</article-title><source>Eur. J. Med. Chem.</source><year>2020</year><volume>208</volume><fpage>112847</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112847</pub-id><pub-id pub-id-type="pmid">33022479</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-18-00275"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>He</surname><given-names>C.-P.</given-names></name>
<name><surname>Diao</surname><given-names>P.-C.</given-names></name>
<name><surname>Hong</surname><given-names>K.H.</given-names></name>
<name><surname>Rao</surname><given-names>J.-J.</given-names></name>
<name><surname>Zhao</surname><given-names>P.-L.</given-names></name>
</person-group><article-title>Discovery and optimization of 3, 4, 5-trimethoxyphenyl substituted triazolylthioacetamides as potent tubulin polymerization inhibitors</article-title><source>Bioorganic Med. Chem. Lett.</source><year>2019</year><volume>29</volume><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2018.11.024</pub-id><pub-id pub-id-type="pmid">30448234</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-18-00275"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verdirosa</surname><given-names>F.</given-names></name>
<name><surname>Gavara</surname><given-names>L.</given-names></name>
<name><surname>Sevaille</surname><given-names>L.</given-names></name>
<name><surname>Tassone</surname><given-names>G.</given-names></name>
<name><surname>Corsica</surname><given-names>G.</given-names></name>
<name><surname>Legru</surname><given-names>A.</given-names></name>
<name><surname>Feller</surname><given-names>G.</given-names></name>
<name><surname>Chelini</surname><given-names>G.</given-names></name>
<name><surname>Mercuri</surname><given-names>P.S.</given-names></name>
<name><surname>Tanfoni</surname><given-names>S.</given-names></name>
</person-group><article-title>1, 2, 4-triazole-3-thione analogues with a 2-ethylbenzoic acid at position 4 as vim-type metallo-&#x003b2;-lactamase inhibitors</article-title><source>ChemMedChem</source><year>2022</year><volume>17</volume><fpage>e202100699</fpage><pub-id pub-id-type="doi">10.1002/cmdc.202100699</pub-id><pub-id pub-id-type="pmid">35050549</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00275"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Claudel</surname><given-names>M.</given-names></name>
<name><surname>Schwarte</surname><given-names>J.V.</given-names></name>
<name><surname>Fromm</surname><given-names>K.M.</given-names></name>
</person-group><article-title>New antimicrobial strategies based on metal complexes</article-title><source>Chemistry</source><year>2020</year><volume>2</volume><fpage>849</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.3390/chemistry2040056</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-18-00275"><label>27.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Lazzarato</surname><given-names>L.</given-names></name>
<name><surname>Failla</surname><given-names>M.</given-names></name>
<name><surname>Gianquinto</surname><given-names>E.</given-names></name>
<name><surname>Bersani</surname><given-names>M.</given-names></name>
<name><surname>Bertarini</surname><given-names>L.</given-names></name>
<name><surname>Verri</surname><given-names>A.</given-names></name>
<name><surname>Vascon</surname><given-names>F.</given-names></name>
<name><surname>Sannio</surname><given-names>F.</given-names></name>
<name><surname>Verdirosa</surname><given-names>F.</given-names></name>
<name><surname>Beatrice</surname><given-names>N.</given-names></name>
</person-group><article-title>Broad spectrum metallo beta-lactamases inhibitors: New tools against clinically-relevant carbapenemases</article-title><source>Book of Abstracts of XXVII National Meeting on Medicinal Chemistry</source><publisher-name>Societ&#x000e0; Chimica Italiana</publisher-name><publisher-loc>Rome, Italy</publisher-loc><year>2022</year><fpage>42</fpage></element-citation></ref><ref id="B28-pharmaceuticals-18-00275"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>N.</given-names></name>
<name><surname>Guan</surname><given-names>Q.</given-names></name>
<name><surname>Hong</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Wu</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
</person-group><article-title>Discovery of 6-aryl-2-(3, 4, 5-trimethoxyphenyl) thiazole [3, 2-b][1,2,4] triazoles as potent tubulin polymerization inhibitors</article-title><source>Eur. J. Med. Chem.</source><year>2023</year><volume>256</volume><fpage>115402</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115402</pub-id><pub-id pub-id-type="pmid">37182330</pub-id>
</element-citation></ref><ref id="B29-pharmaceuticals-18-00275"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dhuguru</surname><given-names>J.</given-names></name>
<name><surname>Zviagin</surname><given-names>E.</given-names></name>
<name><surname>Skouta</surname><given-names>R.</given-names></name>
</person-group><article-title>Fda-approved oximes and their significance in medicinal chemistry</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><elocation-id>66</elocation-id><pub-id pub-id-type="doi">10.3390/ph15010066</pub-id><pub-id pub-id-type="pmid">35056123</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-18-00275"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geurs</surname><given-names>S.</given-names></name>
<name><surname>Clarisse</surname><given-names>D.</given-names></name>
<name><surname>De Bosscher</surname><given-names>K.</given-names></name>
<name><surname>D&#x02019;hooghe</surname><given-names>M.</given-names></name>
</person-group><article-title>The zinc-binding group effect: Lessons from non-hydroxamic acid vorinostat analogs</article-title><source>J. Med. Chem.</source><year>2023</year><volume>66</volume><fpage>7698</fpage><lpage>7729</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c00226</pub-id><pub-id pub-id-type="pmid">37276138</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-18-00275"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allen</surname><given-names>L.A.</given-names></name>
<name><surname>Raclea</surname><given-names>R.-C.</given-names></name>
<name><surname>Natho</surname><given-names>P.</given-names></name>
<name><surname>Parsons</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Recent advances in the synthesis of &#x003b1;-amino ketones</article-title><source>Org. Biomol. Chem.</source><year>2021</year><volume>19</volume><fpage>498</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1039/D0OB02098B</pub-id><pub-id pub-id-type="pmid">33325975</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-18-00275"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wipf</surname><given-names>P.</given-names></name>
<name><surname>Reeves</surname><given-names>J.T.</given-names></name>
<name><surname>Balachandran</surname><given-names>R.</given-names></name>
<name><surname>Day</surname><given-names>B.W.</given-names></name>
</person-group><article-title>Synthesis and biological evaluation of structurally highly modified analogues of the antimitotic natural product curacin a</article-title><source>J. Med. Chem.</source><year>2002</year><volume>45</volume><fpage>1901</fpage><lpage>1917</lpage><pub-id pub-id-type="doi">10.1021/jm0105171</pub-id><pub-id pub-id-type="pmid">11960501</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-18-00275"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alvarez</surname><given-names>C.</given-names></name>
<name><surname>Alvarez</surname><given-names>R.</given-names></name>
<name><surname>Corchete</surname><given-names>P.</given-names></name>
<name><surname>L&#x000f3;pez</surname><given-names>J.L.</given-names></name>
<name><surname>P&#x000e9;rez-Melero</surname><given-names>C.</given-names></name>
<name><surname>Pel&#x000e1;ez</surname><given-names>R.</given-names></name>
<name><surname>Medarde</surname><given-names>M.</given-names></name>
</person-group><article-title>Diarylmethyloxime and hydrazone derivatives with 5-indolyl moieties as potent inhibitors of tubulin polymerization</article-title><source>Bioorganic Med. Chem.</source><year>2008</year><volume>16</volume><fpage>5952</fpage><lpage>5961</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2008.04.054</pub-id></element-citation></ref><ref id="B34-pharmaceuticals-18-00275"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdelbaset</surname><given-names>M.S.</given-names></name>
<name><surname>Abdelrahman</surname><given-names>M.H.</given-names></name>
<name><surname>Bukhari</surname><given-names>S.N.A.</given-names></name>
<name><surname>Gouda</surname><given-names>A.M.</given-names></name>
<name><surname>Youssif</surname><given-names>B.G.</given-names></name>
<name><surname>Abdel-Aziz</surname><given-names>M.</given-names></name>
<name><surname>Abuo-Rahma</surname><given-names>G.E.-D.A.</given-names></name>
</person-group><article-title>Design, synthesis, and biological evaluation of new series of pyrrol-2 (3h)-one and pyridazin-3 (2h)-one derivatives as tubulin polymerization inhibitors</article-title><source>Bioorganic Chem.</source><year>2021</year><volume>107</volume><elocation-id>104522</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioorg.2020.104522</pub-id><pub-id pub-id-type="pmid">33317838</pub-id>
</element-citation></ref><ref id="B35-pharmaceuticals-18-00275"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdelbaset</surname><given-names>M.S.</given-names></name>
<name><surname>Abuo-Rahma</surname><given-names>G.E.-D.A.</given-names></name>
<name><surname>Abdelrahman</surname><given-names>M.H.</given-names></name>
<name><surname>Ramadan</surname><given-names>M.</given-names></name>
<name><surname>Youssif</surname><given-names>B.G.</given-names></name>
<name><surname>Bukhari</surname><given-names>S.N.A.</given-names></name>
<name><surname>Mohamed</surname><given-names>M.F.</given-names></name>
<name><surname>Abdel-Aziz</surname><given-names>M.</given-names></name>
</person-group><article-title>Novel pyrrol-2 (3h)-ones and pyridazin-3 (2h)-ones carrying quinoline scaffold as anti-proliferative tubulin polymerization inhibitors</article-title><source>Bioorganic Chem.</source><year>2018</year><volume>80</volume><fpage>151</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2018.06.003</pub-id></element-citation></ref><ref id="B36-pharmaceuticals-18-00275"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Wahaibi</surname><given-names>L.H.</given-names></name>
<name><surname>Abou-Zied</surname><given-names>H.A.</given-names></name>
<name><surname>Abdelrahman</surname><given-names>M.H.</given-names></name>
<name><surname>Morcoss</surname><given-names>M.M.</given-names></name>
<name><surname>Trembleau</surname><given-names>L.</given-names></name>
<name><surname>Youssif</surname><given-names>B.G.</given-names></name>
<name><surname>Br&#x000e4;se</surname><given-names>S.</given-names></name>
</person-group><article-title>Design and synthesis new indole-based aromatase/inos inhibitors with apoptotic antiproliferative activity</article-title><source>Front. Chem.</source><year>2024</year><volume>12</volume><elocation-id>1432920</elocation-id><pub-id pub-id-type="doi">10.3389/fchem.2024.1432920</pub-id><pub-id pub-id-type="pmid">39308851</pub-id>
</element-citation></ref><ref id="B37-pharmaceuticals-18-00275"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Wahaibi</surname><given-names>L.H.</given-names></name>
<name><surname>Gouda</surname><given-names>A.M.</given-names></name>
<name><surname>Abou-Ghadir</surname><given-names>O.F.</given-names></name>
<name><surname>Salem</surname><given-names>O.I.</given-names></name>
<name><surname>Ali</surname><given-names>A.T.</given-names></name>
<name><surname>Farghaly</surname><given-names>H.S.</given-names></name>
<name><surname>Abdelrahman</surname><given-names>M.H.</given-names></name>
<name><surname>Trembleau</surname><given-names>L.</given-names></name>
<name><surname>Abdu-Allah</surname><given-names>H.H.</given-names></name>
<name><surname>Youssif</surname><given-names>B.G.</given-names></name>
</person-group><article-title>Design and synthesis of novel 2, 3-dihydropyrazino [1, 2-a] indole-1, 4-dione derivatives as antiproliferative egfr and brafv600e dual inhibitors</article-title><source>Bioorganic Chem.</source><year>2020</year><volume>104</volume><elocation-id>104260</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioorg.2020.104260</pub-id><pub-id pub-id-type="pmid">32920363</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-18-00275"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Wahaibi</surname><given-names>L.H.</given-names></name>
<name><surname>Mohammed</surname><given-names>A.F.</given-names></name>
<name><surname>Abdel Rahman</surname><given-names>F.E.-Z.S.</given-names></name>
<name><surname>Abdelrahman</surname><given-names>M.H.</given-names></name>
<name><surname>Gu</surname><given-names>X.</given-names></name>
<name><surname>Trembleau</surname><given-names>L.</given-names></name>
<name><surname>Youssif</surname><given-names>B.G.</given-names></name>
</person-group><article-title>Design, synthesis, apoptotic, and antiproliferative effects of 5-chloro-3-(2-methoxyvinyl)-indole-2-carboxamides and pyrido [3, 4-b] indol-1-ones as potent egfrwt/egfrt790m inhibitors</article-title><source>J. Enzym. Inhib. Med. Chem.</source><year>2023</year><volume>38</volume><fpage>2218602</fpage><pub-id pub-id-type="doi">10.1080/14756366.2023.2218602</pub-id><pub-id pub-id-type="pmid">37254958</pub-id>
</element-citation></ref><ref id="B39-pharmaceuticals-18-00275"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ezekwem</surname><given-names>J.E.</given-names></name>
<name><surname>Visagaperumal</surname><given-names>D.</given-names></name>
<name><surname>Chandy</surname><given-names>V.</given-names></name>
</person-group><article-title>Synthesis, characterization and anti-bacterial activity of isatin schiff base derivatives</article-title><source>Asian J. Chem. Pharm. Sci.</source><year>2018</year><volume>3</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.18311/ajcps/2018/21443</pub-id></element-citation></ref><ref id="B40-pharmaceuticals-18-00275"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>M.K.</given-names></name>
<name><surname>Man</surname><given-names>R.J.</given-names></name>
<name><surname>Liao</surname><given-names>Y.J.</given-names></name>
<name><surname>Zhu</surname><given-names>H.L.</given-names></name>
<name><surname>Zhou</surname><given-names>Z.G.</given-names></name>
</person-group><article-title>Discovery of novel indole-1, 2, 4-triazole derivatives as tubulin polymerization inhibitors</article-title><source>Drug Dev. Res.</source><year>2021</year><volume>82</volume><fpage>1008</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1002/ddr.21805</pub-id><pub-id pub-id-type="pmid">33675542</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-18-00275"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verma</surname><given-names>G.</given-names></name>
<name><surname>Chashoo</surname><given-names>G.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
<name><surname>Khan</surname><given-names>M.F.</given-names></name>
<name><surname>Akhtar</surname><given-names>W.</given-names></name>
<name><surname>Ali</surname><given-names>I.</given-names></name>
<name><surname>Akhtar</surname><given-names>M.</given-names></name>
<name><surname>Alam</surname><given-names>M.M.</given-names></name>
<name><surname>Shaquiquzzaman</surname><given-names>M.</given-names></name>
</person-group><article-title>Synthesis of pyrazole acrylic acid based oxadiazole and amide derivatives as antimalarial and anticancer agents</article-title><source>Bioorganic Chem.</source><year>2018</year><volume>77</volume><fpage>106</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2018.01.007</pub-id></element-citation></ref><ref id="B42-pharmaceuticals-18-00275"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohassab</surname><given-names>A.M.</given-names></name>
<name><surname>Hassan</surname><given-names>H.A.</given-names></name>
<name><surname>Abdelhamid</surname><given-names>D.</given-names></name>
<name><surname>Abdel-Aziz</surname><given-names>M.</given-names></name>
<name><surname>Dalby</surname><given-names>K.N.</given-names></name>
<name><surname>Kaoud</surname><given-names>T.S.</given-names></name>
</person-group><article-title>Novel quinoline incorporating 1, 2, 4-triazole/oxime hybrids: Synthesis, molecular docking, anti-inflammatory, cox inhibition, ulceroginicity and histopathological investigations</article-title><source>Bioorganic Chem.</source><year>2017</year><volume>75</volume><fpage>242</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2017.09.018</pub-id><pub-id pub-id-type="pmid">29032325</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-18-00275"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shoemaker</surname><given-names>R.H.</given-names></name>
</person-group><article-title>The nci60 human tumour cell line anticancer drug screen</article-title><source>Nat. Rev. Cancer</source><year>2006</year><volume>6</volume><fpage>813</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1038/nrc1951</pub-id><pub-id pub-id-type="pmid">16990858</pub-id>
</element-citation></ref><ref id="B44-pharmaceuticals-18-00275"><label>44.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Boyd</surname><given-names>M.R.</given-names></name>
</person-group><article-title>The NCI in vitro anticancer drug discovery screen: Concept, implementation, and operation, 1985&#x02013;1995</article-title><source>Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>1997</year><fpage>23</fpage><lpage>42</lpage></element-citation></ref><ref id="B45-pharmaceuticals-18-00275"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>M.H.</given-names></name>
<name><surname>Smith</surname><given-names>M.A.</given-names></name>
<name><surname>Morton</surname><given-names>C.L.</given-names></name>
<name><surname>Keshelava</surname><given-names>N.</given-names></name>
<name><surname>Houghton</surname><given-names>P.J.</given-names></name>
<name><surname>Reynolds</surname><given-names>C.P.</given-names></name>
</person-group><article-title>National cancer institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing</article-title><source>Pediatr. Blood Cancer</source><year>2011</year><volume>56</volume><fpage>239</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1002/pbc.22801</pub-id><pub-id pub-id-type="pmid">20922763</pub-id>
</element-citation></ref><ref id="B46-pharmaceuticals-18-00275"><label>46.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Boyd</surname><given-names>M.R.</given-names></name>
</person-group><article-title>The NCI human tumor cell line (60-cell) screen: Concept, implementation, and applications</article-title><source>Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2004</year><fpage>41</fpage><lpage>61</lpage></element-citation></ref><ref id="B47-pharmaceuticals-18-00275"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El-Sherief</surname><given-names>H.A.</given-names></name>
<name><surname>Youssif</surname><given-names>B.G.</given-names></name>
<name><surname>Bukhari</surname><given-names>S.N.A.</given-names></name>
<name><surname>Abdelazeem</surname><given-names>A.H.</given-names></name>
<name><surname>Abdel-Aziz</surname><given-names>M.</given-names></name>
<name><surname>Abdel-Rahman</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Synthesis, anticancer activity and molecular modeling studies of 1, 2, 4-triazole derivatives as egfr inhibitors</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>156</volume><fpage>774</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.07.024</pub-id><pub-id pub-id-type="pmid">30055463</pub-id>
</element-citation></ref><ref id="B48-pharmaceuticals-18-00275"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gaspari</surname><given-names>R.</given-names></name>
<name><surname>Prota</surname><given-names>A.E.</given-names></name>
<name><surname>Bargsten</surname><given-names>K.</given-names></name>
<name><surname>Cavalli</surname><given-names>A.</given-names></name>
<name><surname>Steinmetz</surname><given-names>M.O.</given-names></name>
</person-group><article-title>Structural basis of cis-and trans-combretastatin binding to tubulin</article-title><source>Chem</source><year>2017</year><volume>2</volume><fpage>102</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.chempr.2016.12.005</pub-id></element-citation></ref><ref id="B49-pharmaceuticals-18-00275"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rehulka</surname><given-names>J.</given-names></name>
<name><surname>Subtelna</surname><given-names>I.</given-names></name>
<name><surname>Kryshchyshyn-Dylevych</surname><given-names>A.</given-names></name>
<name><surname>Cherniienko</surname><given-names>A.</given-names></name>
<name><surname>Ivanova</surname><given-names>A.</given-names></name>
<name><surname>Matveieva</surname><given-names>M.</given-names></name>
<name><surname>Polishchuk</surname><given-names>P.</given-names></name>
<name><surname>Gurska</surname><given-names>S.</given-names></name>
<name><surname>Hajduch</surname><given-names>M.</given-names></name>
<name><surname>Zagrijtschuk</surname><given-names>O.</given-names></name>
</person-group><article-title>Anticancer 5-arylidene-2-(4-hydroxyphenyl) aminothiazol-4 (5h)-ones as tubulin inhibitors</article-title><source>Arch. Pharm.</source><year>2022</year><volume>355</volume><fpage>2200419</fpage><pub-id pub-id-type="doi">10.1002/ardp.202200419</pub-id><pub-id pub-id-type="pmid">36109178</pub-id>
</element-citation></ref><ref id="B50-pharmaceuticals-18-00275"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mekheimer</surname><given-names>R.A.</given-names></name>
<name><surname>Allam</surname><given-names>S.M.</given-names></name>
<name><surname>Al-Sheikh</surname><given-names>M.A.</given-names></name>
<name><surname>Moustafa</surname><given-names>M.S.</given-names></name>
<name><surname>Al-Mousawi</surname><given-names>S.M.</given-names></name>
<name><surname>Mostafa</surname><given-names>Y.A.</given-names></name>
<name><surname>Youssif</surname><given-names>B.G.</given-names></name>
<name><surname>Gomaa</surname><given-names>H.A.</given-names></name>
<name><surname>Hayallah</surname><given-names>A.M.</given-names></name>
<name><surname>Abdelaziz</surname><given-names>M.</given-names></name>
</person-group><article-title>Discovery of new pyrimido [5, 4-c] quinolines as potential antiproliferative agents with multitarget actions: Rapid synthesis, docking, and adme studies</article-title><source>Bioorganic Chem.</source><year>2022</year><volume>121</volume><elocation-id>105693</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioorg.2022.105693</pub-id></element-citation></ref><ref id="B51-pharmaceuticals-18-00275"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahmoud</surname><given-names>M.A.</given-names></name>
<name><surname>Mohammed</surname><given-names>A.F.</given-names></name>
<name><surname>Salem</surname><given-names>O.I.</given-names></name>
<name><surname>Gomaa</surname><given-names>H.A.</given-names></name>
<name><surname>Youssif</surname><given-names>B.G.</given-names></name>
</person-group><article-title>New 1, 3, 4-oxadiazoles linked with the 1, 2, 3-triazole moiety as antiproliferative agents targeting the egfr tyrosine kinase</article-title><source>Arch. Pharm.</source><year>2022</year><volume>355</volume><fpage>2200009</fpage><pub-id pub-id-type="doi">10.1002/ardp.202200009</pub-id></element-citation></ref><ref id="B52-pharmaceuticals-18-00275"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohamed</surname><given-names>A.M.</given-names></name>
<name><surname>Abou-Ghadir</surname><given-names>O.M.</given-names></name>
<name><surname>Mostafa</surname><given-names>Y.A.</given-names></name>
<name><surname>Dahlous</surname><given-names>K.A.</given-names></name>
<name><surname>Br&#x000e4;se</surname><given-names>S.</given-names></name>
<name><surname>Youssif</surname><given-names>B.G.</given-names></name>
</person-group><article-title>Design and synthesis of new 1, 2, 4-oxadiazole/quinazoline-4-one hybrids with antiproliferative activity as multitargeted inhibitors</article-title><source>Front. Chem.</source><year>2024</year><volume>12</volume><elocation-id>1447618</elocation-id><pub-id pub-id-type="doi">10.3389/fchem.2024.1447618</pub-id><pub-id pub-id-type="pmid">39281035</pub-id>
</element-citation></ref><ref id="B53-pharmaceuticals-18-00275"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Darzynkiewicz</surname><given-names>Z.</given-names></name>
<name><surname>Bedner</surname><given-names>E.</given-names></name>
<name><surname>Smolewski</surname><given-names>P.</given-names></name>
</person-group><article-title>Flow cytometry in analysis of cell cycle and apoptosis</article-title><source>Semin. Hematol.</source><year>2001</year><volume>38</volume><fpage>179</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/S0037-1963(01)90051-4</pub-id><pub-id pub-id-type="pmid">11309699</pub-id>
</element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Scheme and Tables</title><fig position="float" id="pharmaceuticals-18-00275-f001"><label>Figure 1</label><caption><p>Structure of CA-4 (<bold>I</bold>), isoCA-4 (<bold>II</bold>), and compounds <bold>III</bold> and <bold>IV</bold>.</p></caption><graphic xlink:href="pharmaceuticals-18-00275-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00275-f002"><label>Figure 2</label><caption><p>Structure of oxime-based binding tubulin compounds <bold>V</bold> and <bold>VI</bold>.</p></caption><graphic xlink:href="pharmaceuticals-18-00275-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00275-f003"><label>Figure 3</label><caption><p>Structures of new targets <bold>6a</bold>&#x02013;<bold>j</bold> and <bold>7a</bold>&#x02013;<bold>j</bold>.</p></caption><graphic xlink:href="pharmaceuticals-18-00275-g003" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00275-f004"><label>Figure 4</label><caption><p>Cell cycle analysis of <bold>7i</bold> in MDA-MB 231 cell line.</p></caption><graphic xlink:href="pharmaceuticals-18-00275-g004" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00275-f005"><label>Figure 5</label><caption><p>Results for apoptosis induction assay of <bold>7i</bold>.</p></caption><graphic xlink:href="pharmaceuticals-18-00275-g005" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00275-f006"><label>Figure 6</label><caption><p>Results for cell cycle analysis and apoptosis induction of <bold>7i</bold>.</p></caption><graphic xlink:href="pharmaceuticals-18-00275-g006" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00275-f007"><label>Figure 7</label><caption><p>Ligplots at &#x003b1;/&#x003b2;-tubulin colchicine binding site: (<bold>A</bold>) 3D-docked model of CA-4 (dark yellow) showing the protein lipophilicity surface (purple: hydrophilic, white: neutral, and green: lipophilic), (cyan for &#x003b1; chain residues and brown for &#x003b2; chain residues), and (<bold>B</bold>) 2D-docked model of CA-4.</p></caption><graphic xlink:href="pharmaceuticals-18-00275-g007" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00275-f008"><label>Figure 8</label><caption><p>Ligplots at &#x003b1;/&#x003b2;-tubulin colchicine binding site: (<bold>A</bold>) a 3D-docked model of compound <bold>7i</bold> (grey) showing the protein lipophilicity surface (purple: hydrophilic, white: neutral, and green: lipophilic), (cyan for &#x003b1; chain residues and brown for &#x003b2; chain residues), and (<bold>B</bold>) a 2D-docked model of <bold>7i</bold>.</p></caption><graphic xlink:href="pharmaceuticals-18-00275-g008" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00275-f009"><label>Figure 9</label><caption><p>Ligplots at &#x003b1;/&#x003b2;-tubulin colchicine binding site: (<bold>A</bold>) 3D-docked model of compound <bold>6h</bold> (dark yellow) showing the protein lipophilicity surface (purple: hydrophilic, white: neutral, and green: lipophilic), (cyan for &#x003b1; chain residues and brown for &#x003b2; chain residues), and (<bold>B</bold>) 2D-docked model of <bold>6h</bold>.</p></caption><graphic xlink:href="pharmaceuticals-18-00275-g009" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00275-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00275-t001_Table 1</object-id><label>Table 1</label><caption><p>Cell growth inhibition % from the NCI&#x02019;s in vitro human tumor cell lines screen for the most active compounds <bold>6h, 7h, 7i,</bold> and <bold>7j</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Subpanel Cancer Cell Lines</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Compound</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7i</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7j</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCRF-CEM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">135</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105.19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HL-60(TB)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">113.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">136.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">125.94</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K-562</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.07</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MOLT-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">127.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">119.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107.37</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RPMI-8226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">119.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">113.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">113.41</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.71</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.18</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-small cell lung cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549/ATCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">118.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.52</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EKVX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.98</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">163.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.95</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOP-62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">156.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">154.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">164.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOP-92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108.42</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">141.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">141.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85.66</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.69</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H322M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">142.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">172.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">149.35</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H460</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70.73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">121.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.51</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H522</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">129.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.63</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COLO 205</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.98</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">141.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.79</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCC-2998</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">141.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83.03</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCT-116</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">136.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.26</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCT-15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">162.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">192.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">148.11</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HT29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">176.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.53</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KM12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.61</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SW-620</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">180.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">186.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">137</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CNS cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-268</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">160.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">155.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">149.04</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-295</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">149.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">114.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85.93</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-539</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">164.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70.52</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNB-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">118.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82.56</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNB-75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">101.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">144.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">119.93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.98</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U251</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69.48</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LOX IMVI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">119.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">188.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">187.44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">189.32</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MALME-3M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.86</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">164.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">167.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">147.28</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-435</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">199.76</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">79.86</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">126.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.78</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">124.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.78</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UACC-257</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.74</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UACC-62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">152.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">190.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">143.19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IGROV1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">162.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">165.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">134.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.77</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">115.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">187.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">183.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">181.32</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">148.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">182.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">143.38</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.71</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">127.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">141.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.63</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI/ADR-RES</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">127.71</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">168.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">173.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">170.19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-OV-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">101.58</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Renal cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">786-0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">135.44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.86</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A498</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.29</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACHN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">79.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">161.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">183.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.66</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAKI-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">127.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">194.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110.75</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SN12C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">136.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">177.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">116.18</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TK-10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">165.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">182.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">123.17</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UO-31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.61</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prostate cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PC-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">146.54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">164.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">138.01</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DU-145</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">160.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">188.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">130.92</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCF7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">154.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">142.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.73</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-231/ATCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">182.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">184.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">154.53</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS 578 T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">153.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">139.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">131.67</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BT-549</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">175.54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">172.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166.72</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T-47D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">147.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.09</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-468</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">188.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">194.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">185.12</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00275-t002"><object-id pub-id-type="pii">pharmaceuticals-18-00275-t002_Table 2</object-id><label>Table 2</label><caption><p>Screening results of compound <bold>6h</bold> at five dose levels in &#x000b5;M.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Panel</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Cell Lines</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">GI<sub>50</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TGI</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">LC<sub>50</sub></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conc. per Cell Lines</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subpanel<break/>MID <sup>b</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Selectivity Ratio (MID <sup>a</sup>/MID <sup>b</sup>)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conc. per Cell Lines</th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Leukemia</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCRF-CEM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54.40</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">33.48</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HL-60(TB)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K-562</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MOLT-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RPMI-8226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Non-small cell lung cancer</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549/ATCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.90</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">14.93</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EKVX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOP-62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80.00</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOP-92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82.10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69.80</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54.90</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H322M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H460</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63.50</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H522</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Colon cancer</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COLO205</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.40</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">25.39</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCC-2998</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCT-116</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCT-15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HT29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KM12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SW-620</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>CNS cancer</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-268</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.20</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">17.35</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-295</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.30</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-539</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54.20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNB-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.30</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNB-75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.00</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U251</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Melanoma</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LOX IMVI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.30</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">21.77</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.22</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MALME-3M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.06</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-435</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.40</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UACC-257</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UACC-62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.10</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ovarian cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IGROV1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.10</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">17.40</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.00</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.50</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI/ADR-RES</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.80</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-OV-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64.40</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Renal cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">786-0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.70</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">16.98</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66.40</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A498</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACHN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.30</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAKI-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.40</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RXF393</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.50</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SN12C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TK-10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85.00</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UO-31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69.50</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prostate cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PC-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.40</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">8.42</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DU-145</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCF7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.70</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">18.00</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA/MB-231-ATCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69.00</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS 578T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BT-549</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T-47D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-468</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.30</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MID <sup>a</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Average sensitivity of all cell lines in &#x000b5;M. <sup>b</sup> Average sensitivity of all cell lines of a particular subpanel in &#x000b5;M.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00275-t003"><object-id pub-id-type="pii">pharmaceuticals-18-00275-t003_Table 3</object-id><label>Table 3</label><caption><p>Screening results of compound <bold>7h</bold> at five dose levels in &#x000b5;M.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Panel</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Cell Lines</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">GI<sub>50</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TGI</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">LC<sub>50</sub></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conc. per Cell Lines</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subpanel<break/>MID <sup>b</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Selectivity Ratio (MID <sup>a</sup>/MID <sup>b</sup>)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conc. per Cell Lines</th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCRF-CEM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.14</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.03</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.98</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HL-60(TB)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K-562</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MOLT-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RPMI-8226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nd</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Non-small cell lung cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549/ATCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.55</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4.44</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EKVX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOP-62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.93</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOP-92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.91</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H322M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H460</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.55</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H522</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Colon cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COLO205</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.77</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.128</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.959</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCC-2998</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.39</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCT-116</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCT-15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.37</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HT29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KM12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SW-620</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.04</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CNS cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-268</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.99</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.86</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-295</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-539</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.43</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNB-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.46</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNB-75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.48</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U251</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LOX IMVI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.75</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.78</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.73</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MALME-3M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-435</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.72</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UACC-257</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nd</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UACC-62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.31</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ovarian cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IGROV1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.09</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.24</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.07</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.04</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.73</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.49</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI/ADR-RES</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.59</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-OV-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.89</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Renal cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">786-0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.00</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5.77</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A498</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACHN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.26</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAKI-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.74</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RXF393</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.65</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SN12C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TK-10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.90</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UO-31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.47</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prostate cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PC-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.77</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.855</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DU-145</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCF7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.42</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.90</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA/MB-231-ATCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.27</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS 578T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BT-549</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.78</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T-47D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-468</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.64</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MID <sup>a</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Average sensitivity of all cell lines in &#x000b5;M. <sup>b</sup> Average sensitivity of all cell lines of a particular subpanel in &#x000b5;M. nd: Not Determined.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00275-t004"><object-id pub-id-type="pii">pharmaceuticals-18-00275-t004_Table 4</object-id><label>Table 4</label><caption><p>Screening results of compound <bold>7i</bold> at five dose levels in &#x000b5;M.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Panel</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Cell Lines</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">GI<sub>50</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TGI</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">LC<sub>50</sub></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conc. per Cell Lines</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subpanel<break/>MID <sup>b</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Selectivity Ratio (MID <sup>a</sup>/MID <sup>b</sup>)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conc. per Cell Lines</th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCRF-CEM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.78</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.29</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HL-60(TB)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K-562</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MOLT-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RPMI-8226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nd</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Non-small cell lung cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549/ATCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.49</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.23</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.00</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EKVX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOP-62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.98</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOP-92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.40</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84.30</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H322M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.30</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H460</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.40</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H522</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.60</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Colon cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COLO205</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.80</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.19</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCC-2998</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.80</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCT-116</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCT-15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HT29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.80</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KM12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SW-620</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.10</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CNS cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-268</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.37</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.15</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-295</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.60</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-539</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.40</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNB-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84.50</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNB-75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U251</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.20</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LOX IMVI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.71</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.89</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.69</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MALME-3M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.00</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-435</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.57</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.50</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.80</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.80</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UACC-257</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72.60</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UACC-62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.93</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ovarian cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IGROV1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.41</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.79</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.30</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.98</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nd</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.59</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI/ADR-RES</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.08</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-OV-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.40</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Renal cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">786-0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.85</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.87</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.98</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.40</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A498</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACHN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.90</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAKI-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.00</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RXF393</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.65</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SN12C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TK-10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.40</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UO-31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.30</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prostate cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PC-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.15</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.1</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DU-145</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCF7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.49</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.73</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA/MB-231-ATCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.71</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.21</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS 578T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BT-549</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T-47D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-468</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.32</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MID <sup>a</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Average sensitivity of all cell lines in &#x000b5;M. <sup>b</sup> Average sensitivity of all cell lines of a particular subpanel in &#x000b5;M.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00275-t005"><object-id pub-id-type="pii">pharmaceuticals-18-00275-t005_Table 5</object-id><label>Table 5</label><caption><p>Screening results of compound <bold>7j</bold> at five dose levels in &#x000b5;M.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Panel</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Cell Lines</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">GI<sub>50</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TGI</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">LC<sub>50</sub></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conc. per Cell Lines</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subpanel<break/>MID <sup>b</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Selectivity Ratio (MID <sup>a</sup>/MID <sup>b</sup>)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conc. per Cell Lines</th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCRF-CEM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.85</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.80</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HL-60(TB)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K-562</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MOLT-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RPMI-8226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Non-small cell lung cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549/ATCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.35</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.86</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.945</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EKVX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOP-62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOP-92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H322M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.71</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H460</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H522</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.7</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Colon cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COLO205</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.47</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.73</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.978</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCC-2998</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCT-116</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCT-15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HT29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KM12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SW-620</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83.2</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CNS cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-268</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.11</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4.78</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.763</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-295</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-539</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNB-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNB-75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U251</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.9</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LOX IMVI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.72</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.42</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MALME-3M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-435</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.71</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UACC-257</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UACC-62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"> Ovarian cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IGROV1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.35</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.61</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI/ADR-RES</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-OV-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.4</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Renal cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">786-0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.29</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5.23</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A498</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACHN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAKI-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RXF393</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SN12C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TK-10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UO-31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.1</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prostate cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PC-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.31</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.45</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DU-145</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCF7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.63</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.93</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA/MB-231-ATCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c3;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS 578T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BT-549</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.71</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.28</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T-47D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-468</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MID <sup>a</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Average sensitivity of all cell lines in &#x000b5;M. <sup>b</sup> Average sensitivity of all cell lines of a particular subpanel in &#x000b5;M.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00275-t006"><object-id pub-id-type="pii">pharmaceuticals-18-00275-t006_Table 6</object-id><label>Table 6</label><caption><p>Tubulin inhibitory assay of compounds <bold>6h</bold>, <bold>7h</bold>, <bold>7i</bold>, and <bold>7j</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<inline-graphic xlink:href="pharmaceuticals-18-00275-i001.jpg"/>
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tubulin Inhibitory Effect, IC<sub>50</sub> (&#x000b5;M)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>6h</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ph</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.50 &#x000b1; 0.30</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<bold>7h</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Ph</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">18.37 &#x000b1; 0.70</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>7i</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ph</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Br</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.03 &#x000b1; 0.11</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<bold>7j</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Ph</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Cl</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">6.26 &#x000b1; 0.15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>5</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>CA-4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.33 &#x000b1; 0.29</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00275-t007"><object-id pub-id-type="pii">pharmaceuticals-18-00275-t007_Table 7</object-id><label>Table 7</label><caption><p>Ligand&#x02013;protein complex interactions of the tested compounds <bold>6h</bold>, <bold>7h</bold>, <bold>7i</bold>, and <bold>7j</bold> within the colchicine binding site of tubulin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compd.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MOE Score<break/>kcal/mol</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">H-Bond <break/>Interactions (&#x000c5;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Hydrophobic<break/>Interactions</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pi-H Interactions (&#x000c5;)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>CA-4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;8.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;Thr179 (3.42, 3.36)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;Asn258,&#x003b1;Ala316, &#x003b2;Cys241, &#x003b2;Leu248, &#x003b2;Lys352, &#x003b2;Ala250, &#x003b2;Leu255, &#x003b2;Ala316,</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>6h</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;7.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;Asn258, &#x003b2;Lys352, &#x003b1;Thr179, &#x003b2;Leu255, &#x003b2;Cys241, &#x003b2;Leu248, &#x003b1;Asn349, &#x003b2;Ala316</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;Val181 (3.95)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>7h</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;8.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;Met259 (2.90)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;Leu255, &#x003b2;Cys241, &#x003b2;Leu248, &#x003b1;Asn349, &#x003b2;Ala316, &#x003b2;Asn258, &#x003b2;Lys352, &#x003b1;Thr179</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;Asn101 (4.45) &#x003b2;Leu248 (3.84) Leu255 (3.92) Lys352 (3.67)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>7i</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;7.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;Met259 (3.84, 3.28) Ala317<break/>(2.70)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;Leu255, &#x003b2;Asn258<break/>&#x003b2;Cys241, &#x003b2;Leu248,<break/>&#x003b1;Asn349, &#x003b2;Ala316, &#x003b2;Lys352, &#x003b1;Thr179</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leu248 (3.78)<break/>Asn258 (3.31)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>7j</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;7.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;Met259 (3.33, 3.80)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;Leu255, &#x003b2;Asn258<break/>&#x003b2;Cys241, &#x003b2;Leu248,<break/>&#x003b1;Asn349, &#x003b2;Ala316, &#x003b2;Lys352, &#x003b1;Thr179.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leu255 (3.67)<break/>Asn258 (3.32)<break/>Lys352 (4.20)</td></tr></tbody></table></table-wrap></sec></back></article>